# EDGAR Filing Document

**Accession Number:** 0001083446
**File Stem:** 0001193125-26-213157
**Filing Date:** 2026-5
**Character Count:** 181737
**Document Hash:** a460c1c2865c84e587a098dc95402d78
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-213157.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001193125-26-213157

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 93

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astrana Health, Inc.
- **CENTRAL INDEX KEY:** 0001083446
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 870042699
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37392
- **FILM NUMBER:** 26955853

**BUSINESS ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801
- **BUSINESS PHONE:** (626) 282-0288

**MAIL ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Apollo Medical Holdings, Inc.
- **DATE OF NAME CHANGE:** 20080715

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SICLONE INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19990413

?xml version='1.0' encoding='ASCII'? 10-Q

**1** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM** 10-Q

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended March 31, 2026

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ___ to ___.

**Commission File No.** 001-37392

![img28552285_0.jpg](img28552285_0.jpg)

Astrana Health, Inc.

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| Delaware | 95-4472349 |
| (State or Other Jurisdiction | (I.R.S. Employer |
| of Incorporation or Organization) | Identification Number) |

---

1668 S. Garfield Avenue**,** **2**<sup>nd</sup> **Floor,** Alhambra**,** California 91801

(Address of principal executive offices and zip code)

**(**626**)** 282-0288

(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock, $0.001 par value per share | ASTH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of May 4, 2026, there were 55,716,220 shares of common stock of the registrant, $0.001 par value per share, issued and outstanding, which includes 6,132,802 treasury shares that are owned by Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), a consolidated affiliate of Astrana Health, Inc. These shares are legally issued and outstanding but treated as treasury shares for accounting purposes.

------

**Astrana Health, Inc.**

**INDEX TO FORM 10-Q FILING**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | &nbsp;&nbsp;**PAGE** |
|  | &nbsp;&nbsp;[<u>Glossary</u>](#glossary) | &nbsp;&nbsp;[<u>3</u>](#glossary) |
|  | &nbsp;&nbsp;[<u>Introductory Note</u>](#introductory_note) | &nbsp;&nbsp;[<u>4</u>](#introductory_note) |
|  | &nbsp;&nbsp;[<u>Note About Forward-Looking Statements</u>](#forward_looking_statements) | &nbsp;&nbsp;[<u>4</u>](#forward_looking_statements) |
|  | &nbsp;&nbsp;[**<u>PART I</u>**](#part_i) |  |
| &nbsp;&nbsp;[<u>ITEM 1</u>](#condensed_consolidated_financial_stmt) | &nbsp;&nbsp;[<u>Condensed Consolidated Financial Statements</u>](#condensed_consolidated_financial_stmt) | &nbsp;&nbsp;[<u>6</u>](#condensed_consolidated_financial_stmt) |
|  | &nbsp;&nbsp;[<u>Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025</u>](#balance_sheets) | &nbsp;&nbsp;[<u>6</u>](#balance_sheets) |
|  | &nbsp;&nbsp;[<u>Condensed Consolidated Statements of Income for the three months ended March 31, 2026 and 2025</u>](#statement_of_income) | &nbsp;&nbsp;[<u>7</u>](#statement_of_income) |
|  | &nbsp;&nbsp;[<u>Condensed Consolidated Statements of Mezzanine Deficit and Stockholders' Equity for the three months ended March 31, 2026 and 2025</u>](#stockholers_equity) | &nbsp;&nbsp;[<u>8</u>](#stockholers_equity) |
|  | &nbsp;&nbsp;[<u>Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025</u>](#statement_of_cash_flow) | &nbsp;&nbsp;[<u>9</u>](#statement_of_cash_flow) |
|  | &nbsp;&nbsp;[<u>Notes to Condensed Consolidated Financial Statements</u>](#notes_to_condensed_financial_statements) | &nbsp;&nbsp;[<u>10</u>](#notes_to_condensed_financial_statements) |
| &nbsp;&nbsp;[<u>ITEM 2</u>](#managements_discussion_and_analysis) | &nbsp;&nbsp;[<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#managements_discussion_and_analysis) | &nbsp;&nbsp;[<u>37</u>](#managements_discussion_and_analysis) |
| &nbsp;&nbsp;[<u>ITEM 3</u>](#disclosures_about_market_risk) | &nbsp;&nbsp;[<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#disclosures_about_market_risk) | &nbsp;&nbsp;[<u>48</u>](#disclosures_about_market_risk) |
| &nbsp;&nbsp;[<u>ITEM 4</u>](#controls_and_procedures) | &nbsp;&nbsp;[<u>Controls and Procedures</u>](#controls_and_procedures) | &nbsp;&nbsp;[<u>48</u>](#controls_and_procedures) |
|  | &nbsp;&nbsp;[**<u>PART II</u>**](#part_ii) |  |
| &nbsp;&nbsp;[<u>ITEM 1</u>](#legal_proceedings) | &nbsp;&nbsp;[<u>Legal Proceedings</u>](#legal_proceedings) | &nbsp;&nbsp;[<u>49</u>](#legal_proceedings) |
| &nbsp;&nbsp;[<u>ITEM 1A</u>](#risk_factors) | &nbsp;&nbsp;[<u>Risk Factors</u>](#risk_factors) | &nbsp;&nbsp;[<u>49</u>](#risk_factors) |
| &nbsp;&nbsp;[<u>ITEM 2</u>](#securities_and_use_of_proceeds) | &nbsp;&nbsp;[<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#securities_and_use_of_proceeds) | &nbsp;&nbsp;[<u>50</u>](#securities_and_use_of_proceeds) |
| &nbsp;&nbsp;[<u>ITEM 3</u>](#defaults_upon_senior_securities) | &nbsp;&nbsp;[<u>Defaults Upon Senior Securities</u>](#defaults_upon_senior_securities) | &nbsp;&nbsp;[<u>50</u>](#defaults_upon_senior_securities) |
| &nbsp;&nbsp;[<u>ITEM 4</u>](#mine_safety_disclosures) | &nbsp;&nbsp;[<u>Mine Safety Disclosures</u>](#mine_safety_disclosures) | &nbsp;&nbsp;[<u>50</u>](#mine_safety_disclosures) |
| &nbsp;&nbsp;[<u>ITEM 5</u>](#other_information) | &nbsp;&nbsp;[<u>Other Information</u>](#other_information) | &nbsp;&nbsp;[<u>50</u>](#other_information) |
| &nbsp;&nbsp;[<u>ITEM 6</u>](#exhibits) | &nbsp;&nbsp;[<u>Exhibits</u>](#exhibits) | &nbsp;&nbsp;[<u>51</u>](#exhibits) |
| &nbsp;&nbsp;[<u>SIGNATURES</u>](#signatures) |  | &nbsp;&nbsp;[<u>53</u>](#signatures) |

---

------

**Glossary**

The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:

---

| | |
|:---|:---|
| ACO LEAD | ACO Long-Term Enhanced ACO Design  |
| ACO REACH | ACO Realizing Equity, Access, and Community Health |
| AHM | Astrana Health Management, Inc. (f/k/a Network Medical Management Inc.) |
| AHMC | AHMC Healthcare Inc. |
| AHMS | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced Health Management Systems, L.P. |
| APC | Allied Physicians of California, a Professional Medical Corporation |
| Astrana | Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.) |
| Astrana Medical | Astrana Health Medical Corporation (f/k/a AP-AMH Medical Corporation) |
| Astrana Care Partners Medical | Astrana Care Partners Medical Corporation (f/k/a AP-AMH 2 Medical Corporation) |
| CFC | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Community Family Care Medical Group IPA, Inc.  |
| CHS | Collaborative Health Systems, LLC, Golden Triangle Physician Alliance, and Heritage Physician Networks |
| CMS | Centers for Medicare & Medicaid Services |
| DMHC | California Department of Managed Health Care |
| IPA | Independent Practice Association |
| MSSP | Medicare Shared Savings Program  |
| Prospect | Certain businesses and assets of Prospect Medical Holdings, Inc. acquired by the Company |
| Sun Labs | Sun Clinical Laboratories, a California corporation |
| VIE | Variable Interest Entity |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

**INTRODUCTORY NOTE**

Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the "Company," "we," "us," "our," and similar words are references to Astrana Health, Inc., a Delaware corporation ("Astrana" or "Astrana Health"), and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities ("VIEs").

This Quarterly Report on Form 10-Q includes the financial statements for the quarter ended March 31, 2026, and provides management's discussion and analysis of the Company's financial condition, results of operations, and other required disclosures, as mandated by the Securities and Exchange Commission (the "SEC").

The Centers for Medicare & Medicaid Services ("CMS") have not reviewed any statements contained in this Report, including statements describing the Company's participation in the ACO Realizing Equity, Access, and Community Health Model ("ACO REACH Model"), in the ACO Long-Term Enhanced ACO Design Model ("ACO LEAD Model"), or in the Medicare Shared Savings Program ("MSSP").

Trade names and trademarks of Astrana and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies' trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.

**NOTE ABOUT FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions; any projections of earnings, revenue, earnings before interest, taxes, depreciation, and amortization ("EBITDA"), Adjusted EBITDA, Adjusted EBITDA margin, adjusted earnings per share ("EPS") - diluted, free cash flow, or other financial items, such as our projected capitation from CMS, our forward-looking guidance, and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers, acquisitions, or dispositions; any statements relating to our completed Prospect acquisition; any statements with respect to dividends or stock repurchases and timing, methods, and payment of same; any statements regarding the outlook of the ACO REACH Model, the ACO LEAD Model, the MSSP, or strategic transactions; any statements relating to delayed payments under, or potential cuts to, Medicaid and/or Medicaid programs and/or changes in federal or state funding policies; any statements regarding management's view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding our ability to remediate the material weakness in our internal control over financial reporting and maintain effective internal control over financial reporting and disclosure controls and procedures; any statements regarding potential changes to our tax structure; any statements regarding future economic conditions or performance; any statements relating to the potential impact of cybersecurity breaches or disruptions to our management information systems or widespread outages, interruptions, or other failures of operational, communication, and other systems; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "think," "plan," "envision," "intend," "continue," "target," "seek," "contemplate," "budgeted," "will," or "would," and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.

------

[<u>**Table of Contents**</u>](#table_of_contents)

Forward-looking statements involve risks and uncertainties, many of which are difficult to predict, are outside of our control, and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, including the risk factors discussed under the heading "Risk Factors" in Part I, Item 1A thereof. Although we believe the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change. Significant risks and uncertainties could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. Any forward-looking statement made by the Company in this Quarterly Report on Form 10-Q speaks only as of the date it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**PART I – FINANCIAL INFORMATION**

**ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**ASTRANA HEALTH, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
|  | **(Unaudited)** |  |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $478383 | $429474 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net (including amounts from related parties) | 467395 | 374465 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable |  | 1799 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 28017 | 26385 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 25647 | 26264 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable | 4658 | 4926 |
| Total current assets | 1004100 | 863313 |
| **Non-current assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 59546 | 57332 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 257118 | 270968 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 874799 | 865305 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable, net of current portion | 26220 | 26220 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable, net of current portion | 49068 | 48724 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments in other entities – equity method | 27257 | 25637 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 33933 | 35738 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 26786 | 25424 |
| Total non-current assets | 1354727 | 1355348 |
| **Total assets** <sup>(1)</sup> | $2358827 | $2218661 |
| **Liabilities, Mezzanine Deficit, and Stockholders' Equity** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $221389 | $195912 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary accounts payable | 3706 | 3524 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 2507 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical liabilities | 439259 | 335705 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 7557 | 7809 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | 47865 | 47865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 23086 | 24458 |
| Total current liabilities | 745369 | 615273 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability | 7399 | 5491 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 30006 | 31552 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, net of current portion and deferred financing costs | 979764 | 990904 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 18833 | 17107 |
| Total non-current liabilities | 1036002 | 1045054 |
| **Total liabilities** <sup>(1)</sup> | 1781371 | 1660327 |
| Commitments and contingencies (Note 11) |  |  |
| **Mezzanine deficit** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") | (237739) | (234962) |
| **Stockholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; and zero shares issued and outstanding as of March 31, 2026 and December 31, 2025 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value per share; 100,000,000 shares authorized, 48,946,399 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of March 31, 2026 and December 31, 2025, respectively | 49 | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 477508 | 470863 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 322711 | 308379 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 800268 | 779291 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-controlling interests | 14927 | 14005 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 815195 | 793296 |
| **Total liabilities, mezzanine deficit, and stockholders' equity** | $2358827 | $2218661 |

---

<sup>(1)</sup> The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include (a) total assets of $1,317.1 million and $1,276.5 million as of March 31, 2026 and December 31, 2025, respectively, that can be used only to settle obligations of the Company's consolidated VIEs and (b) total liabilities of the consolidated VIEs of $394.5 million and $376.0 million as of March 31, 2026 and December 31, 2025, respectively, for which creditors do not have recourse to the general credit of the Company, the VIE's primary beneficiary. These VIE balances do not include $150.4 million of investment in affiliates and $24.4 million of amounts due from affiliates as of March 31, 2026, and $152.2 million of investment in affiliates and $58.3 million of amounts due from affiliates as of December 31, 2025, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 15 — "Variable Interest Entities (VIEs)" for further details.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ASTRANA HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

**(in thousands, except per share data)**

(UNAUDITED)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| **Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitation, net | $892908 | $583963 |
| &nbsp;&nbsp;&nbsp;&nbsp;Risk pool settlements and incentives | 12486 | 14491 |
| &nbsp;&nbsp;&nbsp;&nbsp;Management fee income | 15685 | 2310 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fee-for-service, net | 37831 | 14890 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other revenue | 6190 | 4736 |
| Total revenue | 965100 | 620390 |
| **Operating expenses** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services, excluding depreciation and amortization | 859356 | 549061 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | 61737 | 43897 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 15479 | 6849 |
| Total expenses | 936572 | 599807 |
| **Income from operations** | 28528 | 20583 |
| **Other (expense) income** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 1720 | (867) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (16101) | (7308) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 3816 | 2312 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 1084 | (44) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (loss) | 662 | (5072) |
| Total other expense, net | (8819) | (10979) |
| **Income before provision for income taxes** | 19709 | 9604 |
| Provision for income taxes | 6578 | 3383 |
| **Net income** | 13131 | 6221 |
| Net loss attributable to non-controlling interests | (1305) | (471) |
| **Net income attributable to Astrana Health, Inc.** | $14436 | $6692 |
| **Earnings per share – basic** | $0.30 | $0.14 |
| **Earnings per share – diluted** | $0.29 | $0.14 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ASTRANA HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE DEFICIT AND STOCKHOLDERS' EQUITY**

**(in thousands, except share data)**

(UNAUDITED)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Mezzanine<br>Deficit –<br>Non-Controlling** | **Common Stock Outstanding** | **Common Stock Outstanding** | **Additional<br>Paid-in** | **Retained** | **Non-Controlling** | **Stockholders'** |
|  | **Interest in APC** | **Shares** | **Amount** | **Capital** | **Earnings** | **Interests** | **Equity** |
| **Balance at January 1, 2026** | $(234962) | 48885358 | $49 | $470863 | $308379 | $14005 | $793296 |
| Net (loss) income | (2677) |  |  |  | 14436 | 1372 | 15808 |
| Purchase of non-controlling interests |  |  |  |  |  | (450) | (450) |
| Shares issued for vesting of restricted stock awards and units |  | 138260 |  | (1172) |  |  | (1172) |
| Shares issued for cash and exercise of options |  | 37065 |  | 496 |  |  | 496 |
| Repurchase of subsidiary's shares | (100) |  |  |  |  |  |  |
| Purchase of treasury shares |  | (124747) |  | (2805) |  |  | (2805) |
| Share-based compensation |  |  |  | 9895 |  |  | 9895 |
| Issuance of shares for Employee Stock Purchase Plan ("ESPP") |  | 10463 |  | 231 |  |  | 231 |
| Dividends |  |  |  |  | (104) |  | (104) |
| **Balance at March 31, 2026** | $**(237739)** | **48946399** | $**49** | $**477508** | $**322711** | $**14927** | $**815195** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Mezzanine<br>Deficit –<br>Non-Controlling** | **Common Stock Outstanding** | **Common Stock Outstanding** | **Additional<br>Paid-in** | **Retained** | **Non-Controlling** | **Stockholders'** |
|  | **Interest in APC** | **Shares** | **Amount** | **Capital** | **Earnings** | **Interests** | **Equity** |
| **Balance at January 1, 2025** | $(202558) | 47929872 | $48 | $426389 | $286283 | $4006 | $716726 |
| Net (loss) income | (1564) |  |  |  | 6692 | 1093 | 7785 |
| Purchase of non-controlling interests |  |  |  |  |  | (28) | (28) |
| Shares issued for vesting of restricted stock awards and units |  | 388173 | 1 | (4053) |  |  | (4052) |
| Repurchase of subsidiary's shares | (1316) |  |  |  |  |  |  |
| Share-based compensation |  |  |  | 7867 |  |  | 7867 |
| Issuance of shares for ESPP |  | 10683 |  | 301 |  |  | 301 |
| Dividends | (27295) | 699896 |  | 21935 | (95) |  | 21840 |
| **Balance at March 31, 2025** | $**(232733)** | **49028624** | $**49** | $**452439** | $**292880** | $**5071** | $**750439** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ASTRANA HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)**

(UNAUDITED)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;Net income | $13131 | $6221 |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 15479 | 6849 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance cost | 1134 | 691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 9895 | 7811 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease expense | 2005 | 1287 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax | 1907 | (358) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration liabilities | 581 | 1407 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (2564) | 729 |
| &nbsp;&nbsp;Changes in operating assets and liabilities, net of business combinations | 26488 | (8010) |
| Net cash provided by operating activities | 68056 | 16627 |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;Purchases of property and equipment | (4000) | (3070) |
| &nbsp;&nbsp;Other | 1156 | 676 |
| Net cash used in investing activities | (2844) | (2394) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;Dividends paid | (104) | (5455) |
| &nbsp;&nbsp;Borrowings on debt |  | 412000 |
| &nbsp;&nbsp;Repayment of debt | (11967) | (428232) |
| &nbsp;&nbsp;Deferred financing cost |  | (17241) |
| &nbsp;&nbsp;Taxes paid from net share settlement of restricted stock | (1172) | (4052) |
| &nbsp;&nbsp;Repurchase of treasury shares | (2906) |  |
| &nbsp;&nbsp;Other | 189 | (1190) |
| Net cash used in financing activities | (15960) | (44170) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 49252 | (29937) |
| **Cash, cash equivalents, and restricted cash, beginning of period** | 434045 | 289101 |
| **Cash, cash equivalents, and restricted cash, end of period** | $483297 | $259164 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;Cash paid for income taxes | <sup>(1)</sup> | $4338 |
| &nbsp;&nbsp;Cash paid for interest | $14723 | $7360 |
| **Supplemental disclosures of non-cash investing and financing activities** |  |  |
| &nbsp;&nbsp;Right-of-use assets obtained in exchange for operating lease liabilities | $350 | $5729 |
| &nbsp;&nbsp;Dividend paid in the form of common stock | $— | $21935 |

---

<sup>(1)</sup> Following the adoption of Accounting Standards Codification ("ASC") 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the year ended December 31, 2025 and prospectively. See Note 13 — "Income Taxes" to the condensed consolidated financial statements for income taxes paid for the three months ended March 31, 2026.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying condensed consolidated balance sheets to the total amounts of cash, cash equivalents, and restricted cash shown in the accompanying condensed consolidated statements of cash flows (in thousands).

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Cash and cash equivalents | $478383 | $258517 |
| Restricted cash <sup>(1)</sup> | 4914 | 647 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total cash, cash equivalents, and restricted cash, end of period shown in the statement of cash flows** | $483297 | $259164 |

---

<sup>(1)</sup> Restricted cash is included in other assets on the condensed consolidated balance sheets.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ASTRANA HEALTH, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**1.** **Description of Business**

***Overview***

Unless the context dictates otherwise, references in these notes to the financial statements to the "Company," "we," "us," "our," and similar words are references to Astrana Health, Inc. ("Astrana" or "Astrana Health") and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities ("VIEs").

Headquartered in Alhambra, California, Astrana is a physician-centric, technology-enabled, healthcare management company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to participate in value-based care arrangements, empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana's affiliated physician groups and consolidated subsidiaries and VIEs, the Company delivers value-based care to patients, of whom the majority are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations ("HMOs"), with a small portion of its revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.

***Segments***

The Company's three reportable segments are Care Partners, Care Delivery, and Care Enablement, which are described as follows:

*Care Partners*

The Company's Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company's unique Care Enablement platform and ability to recruit, empower, and incentivize physicians to manage total cost of care effectively, the Company is able to organize partnered providers into successful multi-payer, risk-bearing organizations ("RBOs") that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare Advantage, Medicaid, Commercial, Exchange, and Medicare fee for service ("FFS"). The Company's healthcare delivery entities in this segment consist of a network of RBOs that encompass independent practice associations ("IPAs"), accountable care organizations ("ACOs"), and state-specific entities such as Restricted Knox-Keene licensed health plans in California. These entities are tasked with coordinating and arranging high-quality care for patients within Astrana's ecosystem. This helps ensure seamless continuity of care among patients in different age groups, stages of life, and life circumstances.

*Care Delivery*

The Company's Care Delivery segment is a group of patient-centric, data-driven organizations focused on delivering high-quality, accessible care to all patients. This segment includes the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•An acute care hospital facility and primary care clinics, including post-acute care services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Specialty care clinics and inpatient services, including cardiac care, endocrinology, and ophthalmology, as well as hospitalist and intensivist services; and

------

[<u>**Table of Contents**</u>](#table_of_contents)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, full-service labs, and a specialty pharmacy.

*Care Enablement*

**2.** **Basis of Presentation and Summary of Significant Accounting Policies**

***Basis of Presentation***

The accompanying condensed consolidated balance sheet at December 31, 2025, has been derived from the Company's audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America ("U.S. GAAP"). The accompanying unaudited condensed consolidated financial statements as of March 31, 2026, and for the three months ended March 31, 2026 and 2025, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March 31, 2026, are not necessarily indicative of the results that may be expected for the year ending December 31, 2026, or any future periods.

***Principles of Consolidation***

The condensed consolidated balance sheets as of March 31, 2026, and December 31, 2025, and the condensed consolidated statements of income for the three months ended March 31, 2026 and 2025, include Astrana's wholly owned subsidiaries and consolidated VIEs. All intercompany transactions and balances have been eliminated in consolidation.

The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read, or have access to, the Company's audited consolidated financial statements for the fiscal year ended December 31, 2025.

***Reclassifications***

Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made to reclass investments in privately held entities within other assets on the condensed consolidated balance sheets as of December 31, 2025. These reclassifications were also made to reclass loss on debt extinguishment, unrealized loss on investments, and loss from equity method investments to other within net cash provided by operating activities; proceeds from repayment of promissory notes, including those with related parties, purchase of marketable securities, and distribution from investment – equity method to other within net cash used in investing activities; and payment of

------

[<u>**Table of Contents**</u>](#table_of_contents)

finance lease obligations, proceeds from ESPP purchases, repurchase of subsidiary's shares, and purchase of non-controlling interests to other within net cash used in financing activities for the three months ended March 31, 2025. The reclassifications had no effect on net income, earnings per share, retained earnings, cash flows provided by (used in) operating, investing, or financing activities, or total assets.

***Use of Estimates***

The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment assessment, accrual of medical liabilities (incurred but not reported ("IBNR") claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including estimations of affiliated hospitals' claims costs which involves assumptions for IBNR, such as utilization of healthcare services, historical payment patterns, cost trends, seasonality, changes in membership, and other factors), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.

***Business Combinations***

The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination, which are expensed as incurred.

***Cash, Cash Equivalents, and Restricted Cash***

The Company's cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are readily convertible into known amounts of cash and have original maturities of 90 days or less from their date of purchase to be cash equivalents.

The Company maintains its cash in deposit accounts with several banks, which at times may exceed the insured limits of the Federal Deposit Insurance Corporation ("FDIC"). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of March 31, 2026, and December 31, 2025, the Company's deposit accounts with banks exceeded the FDIC's insured limit by approximately $492.0 million and $447.0 million, respectively. The Company has not experienced any losses to date and conducts ongoing evaluations of these financial institutions to limit the Company's concentration of risk exposure.

Restricted cash consists of cash held as collateral in the event of default as required by certain health plan contracts. Restricted cash is included in other assets in the accompanying condensed consolidated balance sheets.

------

[<u>**Table of Contents**</u>](#table_of_contents)

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying condensed consolidated balance sheets that sum to the total of the same such amounts shown in the accompanying condensed consolidated statement of cash flows (in thousands).

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Cash and cash equivalents | $478383 | $429474 |
| Restricted cash | 4914 | 4571 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total cash, cash equivalents, and restricted cash** | $483297 | $434045 |

---

***Receivables, Other Receivables, and Loans Receivable***

The Company's receivables are comprised of capitation receivables, ACO receivables, FFS receivables, risk pool settlements, incentive receivables, management fee income, and receivables from related parties. The Company's receivables are recorded and stated at the amount expected to be collected.

Capitation receivables relate to each health plan's capitation revenue and are usually received by the Company in the same month or the month following the month of service. ACO receivables are from Centers for Medicare and Medicaid Services ("CMS") related to the Company's participation in the ACO REACH Model and Medicare Shared Savings Program ("MSSP"). Settlements for the current performance year are settled within the following fiscal year. FFS receivables involve the hospital and clinics. Both the hospital and clinics receive amounts from third-party payers and patients for patient care services, while the clinics additionally receive amounts from hospitals. Risk pool settlements and incentive receivables mainly consist of the Company's hospital shared-risk pool receivable, which is recorded based on reports received from the Company's hospital partners and management's estimate of the Company's portion of the estimated risk pool surplus for open performance years. Final settlement of risk pool surplus or deficits occurs within 6 to 12 months after the risk pool performance year is completed.

The Company's receivables from related parties are comprised of hospital-shared risk pool settlements with AHMC Healthcare Inc. ("AHMC"), for which one of the Company's directors is an officer, and management fee income from equity method investments. Hospital-shared risk pool settlement receivables from related parties are recorded quarterly based on reports received from the Company's hospital partners and management's estimate of the Company's portion of the estimated risk pool surplus for open performance years. Final settlement of risk pool surplus or deficits occurs within 18 months after the risk pool performance year is completed.

The Company's receivables, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Receivables, net | $30106 | $31377 |
| Capitation receivables, net | 106285 | 94229 |
| ACO receivables | 194327 | 109777 |
| Fee-for-service receivables, net | 31794 | 45568 |
| Hospital risk pool receivables | 20516 | 17420 |
| Risk pool and incentives receivables, net | 23599 | 24568 |
| Management fee receivables | 12782 | 7073 |
| Receivables from related parties, net | 47986 | 44453 |
| Total receivables, net | $467395 | $374465 |

---

Other receivables consist of amounts due from the seller associated with acquisitions and stop-loss insurance premium reimbursements.

------

[<u>**Table of Contents**</u>](#table_of_contents)

The Company's loans receivable consists of promissory notes that accrue interest per annum and are recorded and stated at amortized cost plus accrued interest. Interest income is accrued based on the outstanding principal amounts. As of March 31, 2026, and December 31, 2025, the balance of the Company's aggregate loans receivable was $53.7 million, of which the loans receivable from related parties in aggregate was $1.3 million and $1.8 million, respectively. For the three months ended March 31, 2026 and 2025, the Company accrued $1.1 million and $1.0 million, respectively, of interest related to loans within interest income on the accompanying condensed consolidated statements of income.

The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company's receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected, and adjustments are recorded when necessary. Reserves are recorded based on historical trends. Any change in such an estimate of reserves is recorded in the period when such change is identified.

Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided, and collection is reasonably likely to occur. The Company continuously monitors its receivable collections and expects that the historical credit loss experienced across its receivables portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses ("CECL") model.

The Company assesses outstanding loans receivable under the CECL model by evaluating the party's ability to pay, which involves reviewing quarterly interest payment history, annually reviewing financial history, assessing the value of any collateral, and reassessing any identified insolvency risk. As of March 31, 2026, the promissory notes are expected to be collected without default.

***Concentrations of Credit Risks***

The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information on how the Company generates revenue by significant revenue streams and by type of direct contracts, as used by the chief operating decision maker ("CODM"). The accompanying condensed consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by each payer type (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Commercial | $85403 | $46081 |
| Medicare | 608116 | 389352 |
| Medicaid | 228572 | 173158 |
| Other third parties | 43009 | 11799 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $965100 | $620390 |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

The Company had major payers that contributed the following percentages of total consolidated net revenue. These payers are primarily within the Care Partners segment.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Payer A | 20.9% | 33.1% |
| Payer B | 13.5% | 15.3% |
| Payer C | \* | 10.5% |
| Payer D | \* | 10.3% |
| Payer E | \* | 10.1% |

---

\* Less than 10% of total revenue.

The Company had major payers that contributed to the following percentages of receivables, net, and other receivables:

---

| | | |
|:---|:---|:---|
|  | **As of March 31,<br>2026** | **As of December 31,<br>2025** |
| Payer A | 39.2% | 27.4% |
| Payer F | \* | 11.0% |

---

\* Less than 10% of receivables, net and other receivables.

***Revenue Recognition***

The Company receives payments from the following sources for services rendered:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Commercial insurers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Federal government under the Medicare program administered by CMS;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•State governments under Medicaid and other programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Other third-party payers (e.g., hospitals and IPAs); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Individual patients and clients.

Revenue primarily consists of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Capitation revenue;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Risk pool settlements and incentives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Management fee income;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•FFS revenue; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Other revenue

------

[<u>**Table of Contents**</u>](#table_of_contents)

Revenue is recorded in the period in which services are rendered, or the period, generally on a monthly basis, in which the Company is obligated to provide services. The form of billing and related collection risk for such services may vary by revenue type and customer.

***Income Taxes***

Federal and state income taxes are computed at currently enacted tax rates, less tax credits, using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

The Company uses a recognition threshold of "more-likely-than-not" and a measurement attribute on all tax positions taken, or expected to be taken, in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.

***Recent Accounting Pronouncements Not Yet Adopted***

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, "Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40)," to provide disaggregated information about certain income statement costs and expenses. ASU 2024-03 is effective for the Company's annual periods beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its condensed consolidated financial statement disclosures.

On May 12, 2025, the FASB issued ASU 2025-03, "Business Combinations (Topic 805) and Consolidation (Topic 810) — Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity," to revise the guidance in ASC 805 on identifying the accounting acquirer in a business combination in which the legal acquiree is a VIE. The ASU is intended to improve comparability between business combinations that involve VIEs and those that do not. ASU 2025-03 is effective for the Company's annual periods beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its condensed consolidated financial statement disclosures.

In September 2025, the FASB issued ASU 2025-06, "Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software" which clarifies and modernizes the accounting for costs related to internal-use software. The amendments in ASU 2025-06 remove all references to project stages and clarify the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for the Company's annual periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its condensed consolidated financial statement disclosures.

Other than the new standards discussed above, there have been no other recent accounting pronouncements not yet adopted that are expected to have significance, or potential significance, to the Company's financial position, results of operations, and cash flows.

**3.** **Business Combination and Goodwill**

***Certain Businesses and Assets of Prospect Medical Holdings, Inc. ("Prospect")***

On July 1, 2025, the Company, and its affiliates, acquired substantially all the assets of certain direct and indirect subsidiaries of PHP Holdings, LLC, such as Prospect Medical Group and Prospect Medical Systems, and all of the outstanding equity interests

------

[<u>**Table of Contents**</u>](#table_of_contents)

of Prospect Health Plan, Inc., and Foothill Regional Medical Center, pursuant to the Asset and Equity Purchase Agreement, dated November 8, 2024 (such assets and equity collectively, "Prospect"). The acquisition significantly expanded the Company's provider network and enhanced its ability to offer increased access, quality, and value to its members. The purchase price for the acquisition was $674.9 million. To finance the acquisition, the Company borrowed $707.3 million from a five-year delayed draw term loan credit facility. See Note 8 — "Credit Facility and Bank Loans" for further information on the Company's debt.

The Company is currently finalizing its valuation of the acquired assets and liabilities. Preliminary amounts have been recorded and are subject to change, primarily for accounts that include the use of estimates, such as medical liabilities, collectability of receivables, accrued expenses, and tax liabilities. The final purchase price allocation may result in adjustments to the amounts presented. During the three months ended March 31, 2026, the Company recorded measurement period adjustments with corresponding changes to goodwill. These adjustments reflect additional information about facts and circumstances that existed as of the acquisition date, primarily related to a $11.3 million increase in accounts payable and accrued expenses.

The following table summarizes the purchase price allocation of the fair value of assets acquired and liabilities assumed at the acquisition date (in thousands):

---

| | |
|:---|:---|
|  | **Prospect** |
| **Purchase consideration:** | $**674902** |
| **Assets:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $124835 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables | 83258 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 3920 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7730 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable | 794 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment | 37499 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets | 193500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 452382 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable, non-current | 278 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 4535 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 6126 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | $914857 |
| **Liabilities:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $104632 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical liabilities | 122267 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 1772 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 320 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability | 5300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 2763 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 2901 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities assumed | $239955 |
| **Total net assets acquired** | $**674902** |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

The table below represents intangible assets acquired in the Prospect acquisition (dollars in thousands):

---

| | | |
|:---|:---|:---|
|  | **Fair Value** | **Useful Life<br>(Years)** |
| &nbsp;&nbsp;&nbsp;&nbsp;License | $1900 | Indefinite |
| &nbsp;&nbsp;&nbsp;&nbsp;Network relationships | 53800 | 15 years |
| &nbsp;&nbsp;&nbsp;&nbsp;Member relationships | 123500 | 12 years |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(1)</sup> | 14300 | 3–10 years |
| **Total intangible assets acquired** | $193500 |  |

---

<sup>(1)</sup> Other consists of management contracts and a trade name.

***Goodwill***

The acquisition was accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based on their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The goodwill is primarily attributable to the scale, skill sets, operations, and synergies from the acquisition, which can be leveraged to expand the Company's network and enhance the value and quality of care the Company provides to its members.

At the time of acquisition, the Company estimates the amount of assets, including identifiable intangible assets, and liabilities based on a valuation and the facts and circumstances available at the time. The Company determines the final value of assets, including identifiable intangible assets, and liabilities as soon as information is available, but no later than one year from the date of acquisition.

The Company had no impairment of its goodwill during the three months ended March 31, 2026 and 2025.

The change in the carrying value of goodwill for the three months ended March 31, 2026 was as follows (in thousands):

---

| | |
|:---|:---|
|  | **Amount** |
| Balance at January 1, 2026 | $865305 |
| Adjustments | 9494 |
| Balance at March 31, 2026 | $874799 |

---

***Unaudited Pro Forma Financial Information***

The *pro forma* financial information in the table below presents the combined results of the Company and the acquisitions that occurred during the year ended December 31, 2025, as if the acquisitions had occurred on January 1, 2025. The *pro forma* financial information presented has been adjusted to exclude Prospect's historical interest expense as all outstanding debt obligations were settled at closing and not assumed by the Company. The *pro forma* financial information presented has been adjusted to include the Company's incremental interest expense, as if the borrowing from the delayed draw term loan credit facility had occurred on January 1, 2025, to finance the purchase of Prospect. The *pro forma* financial information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company, or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.

------

[<u>**Table of Contents**</u>](#table_of_contents)

---

| | |
|:---|:---|
| *(in thousands, except per share amounts)* | **Three Months Ended March 31, 2025** |
| Total revenue | $929306 |
| Net income attributable to Astrana Health, Inc. | $1808 |
| Earnings per share – basic | $0.04 |
| Earnings per share – diluted | $0.04 |

---

**4.** **Intangible Assets, Net**

At March 31, 2026, intangible assets, net, consisted of the following (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Useful<br>Life<br>(Years)** | **Gross<br>March 31,<br>2026** | **Accumulated<br>Amortization** | **Net<br>March 31,<br>2026** |
| Indefinite lived assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks and licenses | N/A | $5950 | $— | $5950 |
| Amortized intangible assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Network relationships | 10–21 | 225717 | (128483) | 97234 |
| &nbsp;&nbsp;&nbsp;&nbsp;Member relationships | 7–14 | 196577 | (57530) | 139047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(1)</sup> | 3–20 | 40310 | (25423) | 14887 |
|  |  | $468554 | $(211436) | $257118 |

---

<sup>(1)</sup> Other consists of management contracts, a patient management platform, trade name/trademarks, and developed technology.

At December 31, 2025, intangible assets, net, consisted of the following (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Useful<br>Life<br>(Years)** | **Gross<br>December 31,<br>2025** | **Accumulated<br>Amortization** | **Net<br>December 31,<br>2025** |
| Indefinite lived assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks and licenses | N/A | $5950 | $— | $5950 |
| Amortized intangible assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Network relationships | 10–21 | 225717 | (125359) | 100358 |
| &nbsp;&nbsp;&nbsp;&nbsp;Member relationships | 7–14 | 196577 | (47908) | 148669 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(1)</sup> | 3–20 | 40310 | (24319) | 15991 |
|  |  | $468554 | $(197586) | $270968 |

---

<sup>(1)</sup> Other consists of management contracts, a patient management platform, trade name/trademarks, and developed technology.

For the three months ended March 31, 2026 and 2025, the Company recognized amortization expense of $13.9 million and $6.3 million, respectively, in depreciation and amortization in the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March 31, 2026 and 2025.

------

[<u>**Table of Contents**</u>](#table_of_contents)

Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):

---

| | |
|:---|:---|
|  | **Amount** |
| 2026 (excluding the three months ended March 31, 2026) | $41258 |
| 2027 | 44125 |
| 2028 | 35715 |
| 2029 | 28621 |
| 2030 | 21687 |
| Thereafter | 79762 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $251168 |

---

**5.** **Investments in Other Entities — Equity Method**

The Company has invested in several entities in the healthcare industry similar to the Care Partners, Care Delivery and Care Enablement segments. The Company holds a range of 25.0% – 51.0% equity interest in these investments that are accounted for under the equity method, as the Company has the ability to exercise significant influence, but not control over operations. Equity method investments are subject to impairment evaluation. No impairment loss was recorded related to equity method investments for the three months ended March 31, 2026 and 2025.

The following table summarizes the Company's equity method investments as of March 31, 2026 and December 31, 2025 (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **% of<br>Ownership** | **March 31,<br>2026** | **December 31,<br>2025** |
| LaSalle Medical Associates – IPA line of business | 25.0% | $15721 | $14742 |
| Third Way Health | 27.7% | 5932 | 6000 |
| Other <sup>(1)</sup> | 25.0% – 51.0% | 5604 | 4895 |
|  |  | $27257 | $25637 |

---

<sup>(1)</sup> Other consists of smaller equity method investments.

The Company records its investments in certain non-consolidated VIEs within investments in other entities – equity method in the accompanying condensed consolidated balance sheets. These entities were determined to be VIEs but are not consolidated. Despite providing financial support to these entities, the Company lacks a controlling financial interest and is not the primary beneficiary. Thus, these VIEs are accounted for under the equity method of accounting. As of March 31, 2026, the Company's maximum exposure to loss was $3.3 million, which represents the carrying value of the Company's investments in the non-consolidated VIEs.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**6.** **Accounts Payable and Accrued Expenses**

The Company's accounts payable and accrued expenses consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Accounts payable and other accruals | $54328 | $47501 |
| Capitation payable | 25513 | 22374 |
| Subcontractor IPA payable | 4512 | 3928 |
| Hospital Quality Assurance Fee Program ("HQAF") payable | 11517 | 11541 |
| Professional fees | 8548 | 4636 |
| Due to related parties | 9617 | 8993 |
| Accrued compensation | 26612 | 31614 |
| Risk pool payable | 19543 | 15830 |
| Provider incentives | 43870 | 36439 |
| Provider payments | 17329 | 13056 |
| Total accounts payable and accrued expenses | $221389 | $195912 |

---

**7.** **Medical Liabilities**

The Company's medical liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **March 31,<br>2025** |
| Medical liabilities, beginning of period | $335705 | $209039 |
| Acquired | (1810) | (8256) |
| Components of medical care costs related to claims incurred: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period | 557518 | 384479 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior periods | (5231) | (658) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total medical care costs | 552287 | 383821 |
| Payments for medical care costs related to claims incurred: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period | (218424) | (229701) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior periods | (221878) | (145938) |
| &nbsp;&nbsp;&nbsp;&nbsp;Claims paid for acquired balance | (6621) | (4864) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total paid | (446923) | (380503) |
| Medical liabilities, end of period | $439259 | $204101 |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

**8.** **Credit Facility and Bank Loans**

The Company's debt balance consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Term Loans | $918276 | $930243 |
| Revolver Loan | 122000 | 122000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt | 1040276 | 1052243 |
| Less: Current portion of debt | (47865) | (47865) |
| Less: Unamortized financing costs | (12647) | (13474) |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | $979764 | $990904 |

---

The estimated fair value of the Company's long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March 31, 2026 and December 31, 2025, the carrying value was not materially different from fair value, as the interest rates on the Company's debt approximated rates currently available to the Company.

The following are the future commitments, as of March 31, 2026, of the Company's debt for the years ending December 31 (in thousands):

---

| | |
|:---|:---|
|  | **Amount** |
| 2026 (excluding the three months ended March 31, 2026) | $35898 |
| 2027 | 65814 |
| 2028 | 71798 |
| 2029 | 89747 |
| 2030 | 777019 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $1040276 |

---

***Credit Facility***

*Second Amended and Restated Credit Agreement*

On February 26, 2025, the Company entered into the Second Amended and Restated Credit Agreement (the "Second Amended and Restated Credit Agreement," and the credit facility thereunder, the "Second Amended and Restated Credit Facility") with Truist Bank, in its capacities as administrative agent for the lenders, issuing bank, swingline lender and a lender, and the banks and other financial institutions from time to time party thereto, to, among other things, amend and restate that certain amended credit agreement, dated June 16, 2021, by and among the Company, Truist Bank, and certain lenders thereto, in its entirety. The Second Amended and Restated Credit Agreement provides for (a) a five-year revolving credit facility ("Revolver Loan") to the Company of $300.0 million, which includes a letter of credit sub-facility of up to $100.0 million and a swingline loan sub-facility of $25.0 million, (b) a five-year term loan A credit facility ("Term Loan") to the Company of $250.0 million, and (c) a five-year delayed draw term loan credit facility ("DDTL A" and together with the Term Loan, the "Term Loans") to the Company of $745.0 million, of which $707.3 million was drawn down in July 2025, with the remaining commitment terminated. The Term Loan and Revolver Loan were used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, pay transaction costs and expenses arising in connection with the Second Amended and Restated Credit Agreement, and provide for working capital needs and other general corporate purposes. The DDTL A was used to fund the Prospect acquisition, and, in addition to the foregoing, the Revolver Loan was used to finance certain future permitted acquisitions and

------

[<u>**Table of Contents**</u>](#table_of_contents)

permitted investments and capital expenditures. As of March 31, 2026, the Company had a combined borrowing of $918.3 million on its Term Loans and $122.0 million under the Revolver Loan under the Second Amended and Restated Credit Agreement. The maturity of the Term Loans and the Revolver Loan is February 26, 2030.

Amounts borrowed under the Second Amended and Restated Credit Agreement bear interest at an annual rate equal to either, at the Company's option, (a) the rate for term Secured Overnight Financing Rate ("SOFR") published by the CME Group Benchmark Administration Limited two days prior to the first day of the applicable interest period, plus a spread of 1.25% to 2.50%, as determined on a quarterly basis based on the Company's leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company's leverage ratio. As of March 31, 2026, interest rates on the Term Loans and $100.0 million of the Revolver Loan were 5.67%, and the interest rate on $22.0 million of the Revolver Loan was 5.68%.

The Second Amended and Restated Credit Agreement requires the Company to pay a commitment fee of 0.175% to 0.35% multiplied by the daily amount of the unused revolving commitments during the availability period, with such fee determined on a quarterly basis based on the Company's leverage ratio, and a ticking fee on the delayed draw term loan facility of 0.175% to 0.35% multiplied by the average daily unused portion of delayed draw term loan commitments, with such fee determined on a quarterly basis based on the Company's leverage ratio. The Company is also required to comply with two financial ratios, each calculated on a consolidated basis. The Company must maintain (commencing with the fiscal quarter ending June 30, 2025) (x) a maximum consolidated total net leverage ratio of not greater than (a) 5.00 to 1.00 as of the last day of each fiscal quarter ending prior to March 31, 2027, and (b) 4.50 to 1.00 as of the last day each fiscal quarter thereafter and (y) a minimum consolidated interest coverage ratio of not less than 2.50 to 1.00 as of the last day of each fiscal quarter. The Second Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, and requiring any new subsidiary meeting a materiality threshold specified in the Second Amended and Restated Credit Agreement to become a guarantor thereunder and paying obligations.

The Second Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company to comply with, restrictions on liens, indebtedness, and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Second Amended and Restated Credit Agreement also contains certain negative covenants binding the Company and its subsidiaries, including restrictions on fundamental changes, dividends and distributions, dispositions, sales and leasebacks, transactions with affiliates, restrictive agreements, use of proceeds, amendments of organizational documents, accounting changes and prepayments, and modifications of subordinated debt.

The Company and its subsidiary Astrana Health Management, Inc. ("AHM") have granted the lenders a security interest in all of their assets, including stock and other equity issued by their subsidiaries, pursuant to the Amended and Restated Guaranty and Security Agreement, dated as of February 26, 2025, by and among the Company, as borrower, and AHM, as guarantor, in favor of Truist Bank, which amends and restates that certain guaranty and security agreement dated as of September 11, 2019, in its entirety. The Second Amended and Restated Credit Agreement contains certain customary events of default. If any event of default occurs and continues under the Second Amended and Restated Credit Agreement, the lenders may terminate their commitments and may require the Company and its guarantors to repay outstanding debt and/or provide a cash deposit as additional security for outstanding letters of credit. In addition, the agent, on behalf of the lenders, may pursue other remedies, including, without limitation, transferring pledged securities of the Company's subsidiaries in the name of the agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables, and other rights provided by law.

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Deferred Financing Costs***

As of March 31, 2026, unamortized deferred financing costs for the Revolver Loan and Term Loans were $4.9 million, and $12.6 million, respectively. As of December 31, 2025, unamortized deferred financing costs for the Revolver Loan and Term Loans were $5.2 million and $13.5 million, respectively. Deferred financing costs associated with the Term Loans are presented as a direct reduction against the amounts borrowed on the Term Loans and amortized over the life of the loans using the effective interest rate method. Deferred financing costs associated with the Revolver Loan are recognized in other assets in the accompanying condensed consolidated balance sheets and amortized over the life of the loan using the straight-line method. Interest expense in the accompanying condensed consolidated statements of income includes amortization of deferred debt issuance costs.

***Effective Interest Rate***

The Company's average effective interest rate on its total debt during the three months ended March 31, 2026 and 2025, was 5.66% and 6.96%, respectively.

**9.** **Mezzanine Deficit and Stockholders' Equity**

***<u>Mezzanine Deficit</u>***

***APC***

As the redemption feature of APC's shares of common stock is not solely within the control of APC, the equity of APC, a consolidated affiliate of the Company, does not qualify as permanent equity and has been classified as non-controlling interest in mezzanine or temporary equity. APC's shares were not redeemable, and it was not probable that the shares would become redeemable as of March 31, 2026 and December 31, 2025.

***<u>Stockholders' Equity</u>***

As of March 31, 2026, 41,048 holdback shares have not been issued to certain former AHM shareholders who were AHM shareholders at the time of closing of the 2017 merger of Astrana with AHM, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their *pro rata* portion of Astrana common stock as contemplated under the 2017 merger agreement. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 merger. The accompanying condensed consolidated financial statements have treated such shares of common stock as outstanding, given that the receipt of the letter of transmittal is considered perfunctory, and the Company is legally obligated to issue these shares in connection with the 2017 merger.

***Treasury Stock***

As of March 31, 2026 and December 31, 2025, APC owned 6,132,802 shares of Astrana's common stock. While such shares of Astrana's common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the accompanying condensed consolidated financial statements. APC's ownership in Astrana was 11.14% and 11.15% as of March 31, 2026 and December 31, 2025, respectively.

During the three months ended March 31, 2026, the Company repurchased 124,747 shares of its common stock for approximately $2.8 million, of which no shares were repurchased from APC. During the three months ended March 31, 2025, the Company repurchased 300,000 shares of its common stock from APC for an aggregate purchase price of approximately $10.6 million. As of March 31, 2026 and December 31, 2025, the Company had repurchased 4,562,956 and 4,438,209 shares, respectively, of its common stock. These are included as treasury stock.

As of March 31, 2026 and December 31, 2025, the total treasury stock, including the Company's stock held by APC, was 10,695,758 and 10,571,011, respectively.

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Dividends***

During the three months ended March 31, 2026, no distributions were made to APC's common shareholders. During the three months ended March 31, 2025, APC distributed 699,896 Astrana shares owned by APC and $5.4 million in cash to its common shareholders. These shares were owned by APC, a consolidated VIE of Astrana, and were carved out from Astrana's economic interest and performance metrics.

**10.** **Stock-Based Compensation**

The Company recognizes stock-based compensation expense associated with the issuance of restricted stock awards, restricted stock units, and shares under the ESPP within cost of services and general and administrative expenses in the accompanying condensed consolidated statements of income.

During the three months ended March 31, 2026 and 2025, the Company recognized $9.9 million and $7.8 million, respectively, in stock-based compensation expense.

As of March 31, 2026, unrecognized compensation expense related to total share-based payments outstanding was $50.9 million.

**11.** **Commitments and Contingencies**

***Regulatory Matters***

Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. While the Company believes it complies with applicable laws and regulations, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action. Failure to comply with such laws and regulations may result in fines, penalties, and/or exclusion from the Medicare and Medi-Cal programs.

The Company's affiliated risk-bearing organizations are required to follow the regulations of the Department of Managed Health Care ("DMHC"). They must comply with a minimum working capital requirement, a tangible net equity ("TNE") requirement, a cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as total assets minus total liabilities, reduced by the value of intangible assets and unsecured obligations of officers, directors, owners, or affiliates outside of the normal course of business, plus subordinated obligations.

Many of the Company's payer and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.

***Standby Letters of Credit and Surety Bonds***

The Company established irrevocable standby letters of credit with Truist Bank under the Second Amended and Restated Credit Agreement for a total of $25.4 million and $25.7 million, for the benefit of CMS and certain health plans as of March 31, 2026 and December 31, 2025, respectively. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional one-year periods from the present or any future expiration date.

Certain affiliated IPAs consolidated by the Company established irrevocable standby letters of credit for a total of $2.1 million for the benefit of certain health plans as of March 31, 2026 and December 31, 2025. The loan under which the standby letters of credit can be issued had an original loan availability of $4.1 million. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.

------

[<u>**Table of Contents**</u>](#table_of_contents)

The Company currently has several surety bonds as required by CMS and other agencies. The bonds total approximately $46.7 million and $46.6 million, in the aggregate, as of March 31, 2026 and December 31, 2025, respectively. The bonds expire on various dates through December 31, 2030.

***Litigation***

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The Company assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, the Company records a liability in its consolidated financial statements. These legal accruals may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable, or the amount of the loss is not estimable, the Company does not record an accrual, consistent with applicable accounting guidance. In the opinion of management, while the outcome of such claims and disputes cannot be predicted with certainty, the Company's ultimate liability in connection with these matters is not expected to have a material adverse effect on the Company's results of operations, financial position, or cash flows, and, except for the matter set forth below, the amounts accrued for any individual matter are not material. However, legal proceedings are inherently uncertain. As a result, the outcome of a particular matter or a combination of matters may be material to the Company's results of operations for a particular period, depending upon the size of the loss or the Company's income for that particular period.

*CFC Health Plan, Inc. – Arbitration Proceeding*

Prior to the acquisition of Advanced Health Management Systems, L.P. ("AHMS") in 2024, CFC Health Plan, Inc. ("CFC HP"), now a wholly owned subsidiary of the Company, was engaged in arbitration with a provider associated with CFC HP ("CFC HP Provider"). Specifically, on or about October 23, 2023, the CFC HP Provider initiated arbitration proceedings by filing a Demand for Arbitration, alleging breach of contract and fraud related to CFC HP's purported failure to pay for services in accordance with the terms of a hospital services agreement (the "CFC HP Arbitration"). On or about August 8, 2025, the CFC HP Provider filed a First Amended Demand for Arbitration, further alleging that CFC HP never intended to comply with the payment terms of the contract. The action was resolved by settlement and dismissed in February 2026. As of December 31, 2025, per the terms of the settlement agreement, the Company paid $12.0 million towards the settlement. In January 2026, the Company paid the final settlement payment in the amount of $1.0 million, and no amounts remained payable as of March 31, 2026.

Given that the CFC HP Provider had already commenced the CFC HP Arbitration at the time of the acquisition of AHMS, as part of the acquisition, the Company and the sellers of CFC HP entered into a side letter to the purchase agreement that required $14.0 million of the purchase price be placed in an escrow account and used as the sole means for satisfying any claims by the Company related to losses incurred in the CFC HP Arbitration. The Company has sought reimbursement for the loss from the CFC HP Arbitration through a claim to the escrow funds. As of March 31, 2026, no loss recovery was recorded.

***Liability Insurance***

The Company believes that its insurance coverage is appropriate based upon the Company's claims experience and the nature and risks of the Company's business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company's affiliated professional organizations, or the Company's affiliated hospitalists in the future, where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims — including potential liabilities in excess of the Company's insurance coverage — will not have a material adverse effect on the Company's financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company's business. Contracted physicians are required to obtain their own insurance coverage.

Although the Company currently maintains liability insurance policies on a claims-made basis, intended to cover malpractice liability and certain other claims, the coverage must be renewed annually and may not continue to be available to the Company in future years at acceptable costs and on favorable terms.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**12.** **Related-Party Transactions**

***Equity Method Investments***

During the three months ended March 31, 2026 and 2025, the Company paid approximately $1.4 million and $3.8 million, respectively, to its equity method investees, for provider, call center, and credentialing services, of which includes $2.2 million to Third Way Health that became an equity method investment in December 2025, and had $6.7 million and $6.8 million in payables for these services as of March 31, 2026 and December 31, 2025, respectively. For one of our equity method investments, Third Way Health, one of Astrana's officers is also a board member. See Note 5 — "Investments in Other Entities — Equity Method".

***Astrana Board Members and Officers***

During the three months ended March 31, 2026 and 2025, the Company incurred rent expenses of approximately $1.3 million and $1.1 million, respectively, from certain properties that are managed by Allied Pacific Holdings Investment Management, LLC. As of March 31, 2026, and December 31, 2025, the Company's operating right-of-use asset balance included $9.7 million and $10.1 million, respectively, and the Company's operating lease liabilities included $10.3 million and $10.7 million, respectively, for certain properties that are managed by Allied Pacific Holdings Investment Management, LLC. The chief executive officer of Allied Pacific Holdings Investment Management, LLC, is a member of the Company's board of directors.

The Company has an agreement with AHMC for services provided to the Company, involving payment for hospital and other inpatient related services, at rates similar to other hospitals which the Company contracts with.

The Company and AHMC also have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. Under this agreement, during the three months ended March 31, 2026 and 2025, the Company had recognized risk pool revenues of $2.1 million and $5.0 million, respectively. As of March 31, 2026 and December 31, 2025, $43.5 million and $40.5 million, respectively, remained in outstanding risk pool receivables.

Revenue with AHMC consists of capitation, risk pool, and miscellaneous fees. Expenses with AHMC primarily include claims expenses. One of the Company's directors is an officer of AHMC. The following table sets forth revenue recognized and fees incurred related to AHMC for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Revenue | $4106 | $6771 |
| Expenses | 45553 | 31680 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net | $(41447) | $(24909) |

---

***APC Board Members***

During the three months ended March 31, 2026 and 2025, the Company paid an aggregate of approximately $5.0 million and $6.5 million, respectively, to board members for provider services, which included approximately $1.0 million, to Astrana board members who are also board members and officers of APC.

***Intercompany Transactions***

Because of corporate practice of medicine laws, the Company uses designated shareholder professional corporations, of which the sole shareholder is a member of the Company's key personnel, to engage in certain transactions and make intercompany loans from time to time. These corporations are reported on a consolidated basis, together with the Company's subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company's subsidiaries as related-party transactions.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**13.** **Income Taxes**

The Company uses the liability method of accounting for income taxes as set forth in ASC 740 "Income Taxes". Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.

On an interim basis, the Company estimates what its anticipated annual effective tax rate will be, and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company's estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined, so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company's deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.

The Company's effective income tax rate for the three months ended March 31, 2026 and 2025, was 33.0% and 35.2%, respectively. The tax rate for the three months ended March 31, 2026, differed from the U.S. federal statutory rate primarily due to non-deductible expenses, state income taxes, and income from flow-through entities.

If recognized, $1.8 million of the unrecognized tax benefits as of March 31, 2026, would reduce the annual effective tax rate. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the Company's condensed consolidated financial statements. For the period ended March 31, 2026, the Company recognized $0.1 million of interest and penalties related to unrecognized tax benefits on the accompanying condensed consolidated balance sheets.

The Company is subject to U.S. federal income tax as well as state income tax in certain U.S. states. The Company and its subsidiaries' state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2021 through December 31, 2024, and for the years ended December 31, 2022 through December 31, 2024, respectively.

For the three months ended March 31, 2026, no payment was made for income taxes, net of tax refunds.

**14.** **Earnings Per Share**

Basic earnings per share are calculated using the weighted average number of shares of the Company's common stock issued and outstanding during a certain period and are calculated by dividing net income attributable to Astrana by the weighted average number of shares of the Company's common stock issued and outstanding during such period. Diluted earnings per share are calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, the as-if converted method for secured convertible notes and preferred stock, and the treasury stock method for options and common stock warrants. The non-controlling interest in APC is allocated its share of Astrana's income from APC's ownership of Astrana common stock, and this amount is included in the net loss attributable to non-controlling interests in the accompanying condensed consolidated statements of income. Therefore, none of the shares of Astrana held by APC are considered outstanding for the purpose of basic or diluted earnings per share computation.

As of March 31, 2026 and December 31, 2025, total treasury stock, including the Company's stock held by APC, was 10,695,758 and 10,571,011, respectively. These are treated as treasury shares for accounting purposes, and are not included in the number of shares of common stock outstanding used to calculate earnings per share.

The following potentially dilutive outstanding securities were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive or the conditions to issue such shares were not achieved as of March 31, 2026 and 2025, respectively:

------

[<u>**Table of Contents**</u>](#table_of_contents)

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Stock options | 113490 | 125707 |
| Restricted stock awards and units | 1254398 | 409736 |
| Contingently issuable shares | 1072137 | 1120899 |
| &nbsp;&nbsp;Total potentially dilutive securities | 2440025 | 1656342 |

---

Below is a summary of the earnings per share computations:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Earnings per share – basic | $0.30 | $0.14 |
| Earnings per share – diluted | $0.29 | $0.14 |
| Weighted average shares of common stock outstanding – basic | 48853678 | 48470682 |
| Weighted average shares of common stock outstanding – diluted | 49054135 | 48850666 |

---

Below is a summary of the shares included in the diluted earnings per share computations:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Weighted average shares of common stock outstanding – basic | 48853678 | 48470682 |
| Stock options | 15776 | 112858 |
| Restricted stock awards and units | 80445 | 130055 |
| Contingently issuable shares | 104236 | 137071 |
| Weighted average shares of common stock outstanding – diluted | 49054135 | 48850666 |

---

**15.** **Variable Interest Entities ("VIEs")**

The Company's condensed consolidated financial statements include its subsidiaries and consolidated VIEs. A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity's economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.

Some states have laws that prohibit business entities with non-physician owners — such as Astrana and its subsidiaries — from practicing medicine, employing physicians to practice medicine, or exercising control over medical decisions by physicians. These laws are generally referred to as corporate practice of medicine laws. States with corporate practice of medicine laws permit only physicians to practice medicine, exercise control over medical decisions, or engage in certain arrangements with physicians, such as fee-splitting.

Due to these laws, the Company operates by maintaining long-term MSAs with its affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. AHM, a wholly owned subsidiary of the Company, has entered into MSAs with several affiliated IPAs, including APC. In accordance with relevant accounting guidance, APC has been determined to be a VIE of AHM, as AHM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding

------

[<u>**Table of Contents**</u>](#table_of_contents)

clinical decisions) that most significantly affect APC's economic performance. Therefore, APC and its wholly owned subsidiaries and VIEs are consolidated in the accompanying condensed consolidated financial statements.

Certain state laws prohibit a professional corporation that has more than one shareholder from being a shareholder in another professional corporation. As a result, the Company cannot directly own shares in another professional corporation. However, an exception to this regulation permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, the Company designated certain key personnel as the nominee shareholder of professional corporations that hold controlling and non-controlling ownership interests in several medical corporations. Via a Physician Shareholder Agreement with the nominee shareholder, the Company has the ability to designate another person to be the equity holder of the professional corporation. In addition, these entities are managed by the Company's wholly owned MSOs via MSAs. In accordance with relevant accounting guidance, the professional corporations and their consolidated medical corporations are consolidated by the Company in the accompanying condensed consolidated financial statements.

The following table includes assets that can only be used to settle the liabilities of the Company's VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company's VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities of the Company's VIEs, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying condensed consolidated balance sheets (in thousands).

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $239110 | $202164 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net (including amounts from related parties) | 209407 | 208929 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 11279 | 8907 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 10833 | 12946 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable | 725 | 753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount due from affiliates <sup>(1)</sup> | 24372 | 58265 |
| Total current assets | 495726 | 491964 |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| **Non-current assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 42848 | 41646 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 209730 | 216594 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 531541 | 524751 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable, net of current portion | 12405 | 12405 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loans receivable, net of current portion | 167 | 194 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments in other entities – equity method | 18039 | 17069 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in affiliates <sup>(1)</sup> | 150376 | 152155 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 25284 | 26499 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 5720 | 3692 |
| Total non-current assets | 996110 | 995005 |
| **Total assets** | $1491836 | $1486969 |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $128582 | $108309 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary accounts payable | 3706 | 3524 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical liabilities | 200166 | 198919 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax payable | 13163 | 15007 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 5203 | 5473 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 6410 | 6505 |
| Total current liabilities | 357230 | 337737 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability | 7287 | 7159 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 23289 | 24241 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 6718 | 6855 |
| Total non-current liabilities | 37294 | 38255 |
| **Total liabilities** | $394524 | $375992 |

---

<sup>(1)</sup> Investment in affiliates includes APC's investment in Astrana. While such shares of Astrana's common stock are legally issued to APC and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the accompanying condensed consolidated financial statements. Amounts due to, or from, affiliates are receivables or payables with Astrana's subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana's condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**16.** **Leases**

The Company has operating leases for corporate and medical offices. These leases have remaining lease terms ranging from 2 months to 20 years. These renewal terms may include options to extend the leases for up to 7 years and are included in the lease term when it is reasonably certain that the Company will exercise the options. Some lease terms may include options to terminate the leases within one year. These leases consist of fixed or variable payments. Variable lease payments are based on an index or a rate such as the Consumer Price Index.

Leases with an initial term of 12 months or less are not recorded on the accompanying condensed consolidated balance sheets.

Lease expense for the three months ended March 31, 2026 and 2025 were $5.0 million and $3.6 million, respectively, of which operating lease costs were $2.6 million and $2.0 million, respectively, and the remaining amount primarily consisted of short-term lease costs.

Other information related to operating leases was as follows (dollars in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Supplemental Cash Flow Information** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for operating lease liabilities | $2539 | $1784 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets obtained in exchange for new operating lease obligations | $350 | $5729 |

---

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Weighted Average Remaining Lease Term | 6.01 years | 7.22 years |
| Weighted Average Discount Rate | 6.72% | 6.75% |

---

The following are future minimum lease payments under non-cancellable operating leases for the years ending December 31 (in thousands):

---

| | |
|:---|:---|
|  | **Operating<br>Leases** |
| 2026 (excluding the three months ended March 31, 2026) | $7566 |
| 2027 | 8701 |
| 2028 | 7815 |
| 2029 | 6372 |
| 2030 | 5202 |
| Thereafter | 10863 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total future minimum lease payments | 46519 |
| Less: imputed interest | 8956 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities | 37563 |
| Less: current portion | 7557 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term lease liabilities | $30006 |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

**17.** **Segments**

The Company currently has three reportable segments consisting of: 1) Care Partners; 2) Care Delivery; and 3) Care Enablement (See Note 1 — "Description of Business").

The Company's CODM is its Chief Executive Officer. The CODM evaluates the performance of the Company's operating segments based on segment revenue growth and operating income. The CODM uses revenue growth and total segment operating income for budgeting, reviewing results, and assessing performance. The CODM does not evaluate the Company's segments using asset information. The significant segment expenses that comprise operating income, as a measure used by the CODM in evaluating operating segment performance, do not differ from the operating expenses as presented on the accompanying condensed consolidated statements of income.

In the normal course of business, the Company's reportable segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.

Corporate costs are unallocated and primarily include corporate initiatives, corporate infrastructure costs, and corporate shared costs such as finance, human resources, legal, and executive management.

Certain amounts disclosed in prior periods have been recast to conform to the current period presentation. Specifically, depreciation and amortization expense is disclosed separately from general and administrative expenses in the accompanying segment table for the three months ended March 31, 2025. The following tables present information about the Company's segments (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
|  | **Care<br>Partners** | **Care<br>Delivery** | **Care<br>Enablement** | **Intersegment<br>Elimination** | **Corporate<br>Costs** | **Consolidated<br>Total** |
| &nbsp;&nbsp;&nbsp;&nbsp;Third Party | $908791 | $40550 | $15759 | $— | $— | $965100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment | 912 | 44527 | 71986 | (117425) |  |  |
| Total revenues | 909703 | 85077 | 87745 | (117425) |  | 965100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services | 785531 | 72544 | 48704 | (47423) |  | 859356 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | 72546 | 14374 | 17259 | (69974) | 27532 | 61737 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 12170 | 1122 | 1629 |  | 558 | 15479 |
| Total expenses | 870247 | 88040 | 67592 | (117397) | 28090 | 936572 |
| Income (loss) from operations | $39456 | $(2963) | $20153 | $(28)<br><sup>(1)</sup> | $(28090) | $28528 |

---

<sup>(1)</sup> Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table.

------

[<u>**Table of Contents**</u>](#table_of_contents)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
|  | **Care<br>Partners** | **Care<br>Delivery** | **Care<br>Enablement** | **Intersegment<br>Elimination** | **Corporate<br>Costs** | **Consolidated<br>Total** |
| &nbsp;&nbsp;&nbsp;&nbsp;Third Party | $600951 | $16690 | $2749 | $— | $— | $620390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment |  | 16698 | 36813 | (53511) |  |  |
| Total revenues | 600951 | 33388 | 39562 | (53511) |  | 620390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services | 512668 | 27139 | 25818 | (16564) |  | 549061 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | 38755 | 8821 | 9209 | (36950) | 24062 | 43897 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5313 | 536 | 1000 |  |  | 6849 |
| Total expenses | 556736 | 36496 | 36027 | (53514) | 24062 | 599807 |
| Income (loss) from operations | $44215 | $(3108) | $3535 | $3<br><sup>(1)</sup> | $(24062) | $20583 |

---

<sup>(1)</sup> Income (loss) from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table.

**18.** **Fair Value Measurements of Financial Instruments**

The carrying amounts and fair values of the Company's financial instruments as of March 31, 2026, are presented below (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** |  |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market accounts <sup>(1)</sup> | $9676 | $— | $— | $9676 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(2)</sup> | 103 | 24 |  | 127 |
| Total assets | $9779 | $24 | $— | $9803 |
| Liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sun Clinical Laboratories, a California corporation ("Sun Labs") remaining equity interest purchase | $— | $— | $7352 | $7352 |
| &nbsp;&nbsp;&nbsp;&nbsp;Community Family Care Medical Group IPA, Inc. ("'CFC") contingent consideration |  |  | 7303 | 7303 |
| &nbsp;&nbsp;&nbsp;&nbsp;Collaborative Health Systems, LLC, Golden Triangle Physician Alliance, and Heritage Physician Networks ("CHS") contingent consideration |  |  | 7681 | 7681 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(3)</sup> |  |  | 15 | 15 |
| Total liabilities | $— | $— | $22351 | $22351 |

---

<sup>(1)</sup> Included in cash and cash equivalents.

<sup>(2)</sup> Consists of marketable securities and the interest rate swap.

<sup>(3)</sup> Consists of a small contingent consideration liability.

------

[<u>**Table of Contents**</u>](#table_of_contents)

The carrying amounts and fair values of the Company's financial instruments as of December 31, 2025, are presented below (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** |  |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market accounts <sup>(1)</sup> | $8798 | $— | $— | $8798 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities <sup>(2)</sup> | 115 |  |  | 115 |
| Total assets | $8913 | $— | $— | $8913 |
| Liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sun Labs remaining equity interest purchase | $— | $— | $7352 | $7352 |
| &nbsp;&nbsp;&nbsp;&nbsp;CFC contingent consideration |  |  | 7026 | 7026 |
| &nbsp;&nbsp;&nbsp;&nbsp;CHS contingent consideration |  |  | 7378 | 7378 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>(3)</sup> |  | 817 | 15 | 832 |
| Total liabilities | $— | $817 | $21771 | $22588 |

---

<sup>(1)</sup> Included in cash and cash equivalents.

<sup>(2)</sup> Included in prepaid expenses and other current assets.

<sup>(3)</sup> Consists of a small contingent consideration liability and the interest rate swap.

The change in the fair value of Level 3 liabilities is recognized in other income or general and administrative expenses in the accompanying condensed consolidated statements of income. As of March 31, 2026, the reconciliation of Level 3 liabilities was as follows (in thousands):

---

| | |
|:---|:---|
|  | **Amount** |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at January 1, 2026 | $21771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of existing Level 3 liabilities | 580 |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at March 31, 2026 | $22351 |

---

***Derivative Financial Instruments***

*Interest Rate Swap Agreement*

On August 7, 2025, the Company entered into an interest rate swap agreement to effectively convert its floating-rate debt to a fixed-rate basis with the principal objective of eliminating or reducing the variability of cash flows in interest payments associated with the Company's floating-rate debt. The swap involves a notional amount of $200 million, with the Company paying a fixed interest rate of 3.179%. Payments are exchanged monthly, starting August 29, 2025 and continuing through the termination date of August 31, 2029, with the bank having an option to shorten the term to August 31, 2027. See Note 8 — "Credit Facility and Bank Loans" for further information on the Company's debt. The interest rate swap agreement is not designated as a hedging instrument. Changes in the fair value of the contract are recognized as unrealized gain or loss on investments in the accompanying

------

[<u>**Table of Contents**</u>](#table_of_contents)

condensed consolidated statements of income and reflected within other as an adjustment to reconcile net income to cash provided by operating activities in the accompanying condensed consolidated statements of cash flows.

***Remaining Equity Interest Purchase***

In 2021, the Company entered into a financing obligation to purchase the remaining equity interest in Sun Labs. The purchase of the remaining Sun Labs equity value is considered a financing obligation with a carrying value of $7.4 million as of March 31, 2026 and December 31, 2025. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other liabilities in the accompanying condensed consolidated balance sheets.

***Contingent Consideration***

*Community Family Care Medical Group IPA, Inc. ("CFC")*

Upon acquiring certain assets of CFC in 2024, the total consideration of the acquisition included contingent consideration, to be settled in cash. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of membership and assigned probabilities to each such scenario in determining fair value. In 2025, the first metric was achieved and paid. As of March 31, 2026 and December 31, 2025, the second metric was valued at $4.9 million and $4.7 million, respectively, and was included in other liabilities in the accompanying condensed consolidated balance sheets. As of March 31, 2026 and December 31, 2025, the third metric was valued at $2.4 million and $2.3 million, respectively, and was included in other long-term liabilities in the accompanying condensed consolidated balance sheets. Changes in the CFC contingent consideration are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.

*Collaborative Health Systems, LLC, Golden Triangle Physician Alliance, and Heritage Physician Networks ("CHS")*

Upon acquiring 100% of the equity interest of CHS in 2024, the total consideration of the acquisition included contingent consideration, to be settled in cash. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and membership and assigned probabilities to each such scenario in determining fair value. As of March 31, 2026 and December 31, 2025, the CHS 2025 gross profit per total member months metric was not met and the related contingent consideration was not paid, and the CHS contingent consideration was valued at $7.7 million and $7.4 million, respectively. The CHS member enrollment metrics were included in other long-term liabilities in the accompanying condensed consolidated balance sheets. Changes in the CHS contingent consideration are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in Part I, Item 1, "Condensed Consolidated Financial Statements" of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026.*

*In this section, "we," "our," "ours," and "us" refer to Astrana Health, Inc. ("Astrana") and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities ("VIEs").*

**Overview**

Astrana is a leading physician-centric, AI-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, Astrana operates an integrated, value-based healthcare model, that aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. Together with our affiliated physician groups and consolidated entities, we cost-effectively provide coordinated outcomes-based medical care.

Through our risk-bearing organizations with more than 20,000 contracted physicians, we were responsible for coordinating the care for approximately 1.55 million patients as of March 31, 2026. These covered patients are managed care members whose health coverage is provided either through their employers, directly from a health plan, or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to deliver high-quality, cost-effective care.

**Regulatory and Industry Trends**

On April 6, 2026, the Centers for Medicare & Medicaid Services ("CMS") issued its final 2027 Medicare Advantage and Part D payment rates ("2027 CMS Rates"). The final notice saw a modest increase in the ratebook in addition to continuing to use the 2024 Medicare Advantage risk adjustment model for 2027, rather than implementing a proposed updated model. CMS retained two risk adjustment modifications which Astrana estimates will not have material effect on our financials. Astrana believes the higher rates along with the commitment to risk adjustment stability in 2027 will benefit Astrana, and we believe Astrana is well-positioned in the 2027 Medicare Advantage marketplace.

**Key Financial Measures and Indicators**

*Operating Revenues*

Our revenue, which is recorded in the period during which services are rendered and earned, generally on a monthly basis, primarily consists of capitation revenue, risk pool settlements and incentives, management fee income, fee-for-service ("FFS") revenue, and other revenue primarily consisting of revenues earned from maternity care. The form of billing and related collection risk for such services may vary by revenue type and customer.

*Operating Expenses*

Our largest expenses consist of the cost of (a) patient care paid to contracted providers and (b) staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include claims processing, utilization management, contracting, accounting, credentialing, and administrative oversight.

------

[<u>**Table of Contents**</u>](#table_of_contents)

*Adjusted EBITDA and Adjusted EBITDA Margin*

Adjusted EBITDA and Adjusted EBITDA margin are supplemental performance measures of our operations for financial and operational decision-making, and are used as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. We define Adjusted EBITDA margin as Adjusted EBITDA over total revenue.

*Adjusted Net Income Attributable to Astrana and Adjusted Earnings Per Share ("EPS") - Diluted*

Our adjusted EPS - diluted is a supplemental performance measure of our operations for financial and operational decision-making and is used as a supplemental means of evaluating period-to-period comparisons on a consistent basis. We define adjusted EPS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangibles, certain tax adjustments, and amounts related to net income or loss attributable to non-controlling interests.

*Free Cash Flow*

Our free cash flow is a supplemental performance measure of our operations for financial and operational decision-making and is used as a supplemental means of evaluating period-to-period comparisons on a consistent basis and reflects the cash flow trends in our business. We define free cash flow as net cash provided by operating activities minus cash used in purchases of property and equipment.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**Results of Operations**

**Astrana Health, Inc.**

**Condensed Consolidated Statements of Income (in thousands)**

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capitation, net | $892908 | $583963 | $308945 | 53% |
| &nbsp;&nbsp;&nbsp;&nbsp;Risk pool settlements and incentives | 12486 | 14491 | (2005) | (14)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Management fee income | 15685 | 2310 | 13375 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Fee-for-service, net | 37831 | 14890 | 22941 | 154% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other revenue | 6190 | 4736 | 1454 | 31% |
| Total revenue | 965100 | 620390 | 344710 | 56% |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services, excluding depreciation and amortization | 859356 | 549061 | 310295 | 57% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | 61737 | 43897 | 17840 | 41% |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 15479 | 6849 | 8630 | 126% |
| Total expenses | 936572 | 599807 | 336765 | 56% |
| **Income from operations** | 28528 | 20583 | 7945 | 39% |
| **Other (expense) income** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 1720 | (867) | 2587 | (298)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (16101) | (7308) | (8793) | 120% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 3816 | 2312 | 1504 | 65% |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 1084 | (44) | 1128 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (loss) | 662 | (5072) | 5734 | (113)% |
| Total other expense, net | (8819) | (10979) | 2160 | (20)% |
| **Income before provision for income taxes** | 19709 | 9604 | 10105 | 105% |
| Provision for income taxes | 6578 | 3383 | 3195 | 94% |
| **Net income** | 13131 | 6221 | 6910 | 111% |
| Net loss attributable to non-controlling interests | (1305) | (471) | (834) | 177% |
| **Net income attributable to Astrana Health, Inc.** | $14436 | $6692 | $7744 | 116% |
| **Adjusted EBITDA** | $66298 | $36386 | $29912 | 82% |

---

\*Percentage change of over 500%

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Risk-Bearing Organizations and Patients***

As of March 31, 2026 and 2025, we managed a total of 29 and 20 independent risk-bearing organizations, respectively, including both affiliated and non-affiliated. The total number of patients for whom we managed the delivery of healthcare services was approximately 1.55 million and 1.0 million as of March 31, 2026 and 2025, respectively.

***Revenue***

Total revenue for the three months ended March 31, 2026, was $965.1 million, as compared to $620.4 million for the three months ended March 31, 2025, an increase of $344.7 million, or 56%. The increase in revenue was partially attributable to the Prospect acquisition, which contributed $300.2 million of revenue from the acquisition date. In addition, capitation revenue increased by $46.4 million primarily as a result of enrollees transitioning to full risk through our Restricted Knox-Keene plans.

***Cost of Services, Excluding Depreciation and Amortization***

Expenses related to cost of services, excluding depreciation and amortization for the three months ended March 31, 2026, were $859.4 million, as compared to $549.1 million for the same period in 2025, an increase of $310.3 million or 57%. The overall increase was primarily due to increased participation in a value-based Medicare FFS model and medical costs associated with both professional and institutional risk of our Restricted Knox-Keene licensed health plans as a result of our recent acquisitions, of which Prospect contributed approximately $259.3 million from the date of acquisition.

***General and Administrative Expenses***

General and administrative expenses for the three months ended March 31, 2026, was $61.7 million, as compared to $43.9 million for the same period in 2025, an increase of $17.8 million or 41%. The increase was primarily due to $16.4 million from the inclusion of Prospect's results of operations from the date of acquisition as well as other general and administrative expenses to support operational growth.

***Depreciation and Amortization***

Depreciation and amortization expenses for the three months ended March 31, 2026, were $15.5 million, as compared to $6.8 million for the same period in 2025, an increase of $8.6 million or 126%, driven by $9.3 million due to the Prospect acquisition, primarily from the acquisition of its intangible assets. This amount includes depreciation of property and equipment and the amortization of intangible assets.

***Income from Equity Method Investments***

Income from equity method investments for the three months ended March 31, 2026, was $1.7 million, as compared to a loss of $0.9 million for the same period in 2025. This amount includes our portion of the equity method investment's net earnings and losses. This exhibited an increase to income primarily due to Allied Physicians of California, a Professional Medical Corporation's ("APC") equity method investment in LaSalle Medical Associates and more favorable performance by our other equity method investments.

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Interest Expense***

Interest expense for the three months ended March 31, 2026, was $16.1 million, as compared to $7.3 million for the same period in 2025, an increase of $8.8 million or 120%. The increase in interest expense was primarily due to the increased borrowings under the Second Amended and Restated Credit Facility to finance the Prospect acquisition, partially offset by a decrease in interest rates on our floating-rate debt. Our outstanding borrowings, as of March 31, 2026, increased to $1,040.3 million on the Second Amended and Restated Credit Facility from $412.0 million borrowed under the facility as of March 31, 2025. The interest rates on the Term Loans and $100.0 million of the Revolver Loan were 5.67%, and the interest rate on $22.0 million of the Revolver Loan was 5.68% as of March 31, 2026. As of March 31, 2025, the interest rates for the Term Loan and the Revolver Loan were 5.82%.

***Interest Income***

Interest income for the three months ended March 31, 2026, was $3.8 million, as compared to $2.3 million for the same period in 2025, an increase of $1.5 million or 65%. Interest income reflects interest earned on cash held in bank accounts, money market and certificate of deposit accounts, and the interest from our loans receivable. The change in interest income was primarily due to an increase in our cash held in interest bearing bank accounts, including $0.5 million of interest income related to cash accounts from the Prospect acquisition.

***Unrealized Gain (Loss) on Investments***

Unrealized gain on investments for the three months ended March 31, 2026, as compared to the same period in 2025, increased $1.1 million primarily due to change in fair value of our interest rate swap.

***Other Income (Loss)***

Other income for the three months ended March 31, 2026, was $0.7 million, as compared to other loss of $5.1 million for the same period in 2025, an increase of $5.7 million or 113%. The increase in other income was primarily due to debt issuance costs incurred in connection with the Second Amended and Restated Credit Facility in 2025. No similar transaction occurred for the three months ended March 31, 2026.

***Provision for Income Taxes***

Provision for income taxes was $6.6 million for the three months ended March 31, 2026, as compared to $3.4 million for the same period in 2025, an increase of $3.2 million primarily due to an increase in pre-tax income.

***Net Loss Attributable to Non-Controlling Interests***

Net loss attributable to non-controlling interests for the three months ended March 31, 2026, was $1.3 million, as compared to $0.5 million for the same period in 2025, an increase of $0.8 million. The increase was primarily driven by losses in APC.

***Net Income Attributable to Astrana Health, Inc.***

Our net income attributable to Astrana Health, Inc., for the three months ended March 31, 2026, was $14.4 million, as compared to $6.7 million for the same period in 2025, an increase of $7.7 million.

***Adjusted EBITDA***

Adjusted EBITDA for the three months ended March 31, 2026, was $66.3 million, as compared to $36.4 million for the same period in 2025, an increase of $29.9 million, and was primarily due to the Prospect acquisition.

See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin" below for additional information.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**Segment Financial Performance**

We currently have three reportable segments consisting of Care Partners, Care Delivery, and Care Enablement. We evaluate the performance of our operating segments based on segment revenue growth as well as operating income. Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses, separate from non-operating factors. For more information about our segments, see Note 17 — "Segments" to our unaudited condensed consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information.

The following table sets forth our revenue and operating income (loss) by segment for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |
| **Segment Revenue** | **2026** | **2025** | **$ Change** | **% Change** |
| Care Partners | $909703 | $600951 | $308752 | 51% |
| Care Delivery | $85077 | $33388 | $51689 | 155% |
| Care Enablement | $87745 | $39562 | $48183 | 122% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |
| **Segment Operating Income (Loss)** | **2026** | **2025** | **$ Change** | **% Change** |
| Care Partners | $39456 | $44215 | $(4759) | (11)% |
| Care Delivery | $(2963) | $(3108) | $145 | (5)% |
| Care Enablement | $20153 | $3535 | $16618 | 470% |

---

***Care Partners Segment***

Revenue for the three months ended March 31, 2026, was $909.7 million, as compared to $601.0 million for the three months ended March 31, 2025, an increase of $308.8 million. Operating income for the three months ended March 31, 2026, was $39.5 million, as compared to $44.2 million for the three months ended March 31, 2025, a decrease in operating income of $4.8 million. The increase in revenue was primarily due to recent acquisitions within our Care Partners segment, including $266.5 million in revenue from the Prospect acquisition, and members transitioning to full risk through our Restricted Knox-Keene plans. The decrease in operating income was primarily due to slightly higher growth in our cost of services expense compared to corresponding revenue related to our increased participation in value-based care and medical costs associated with both professional and institutional risk of our Restricted Knox-Keene licensed health plans.

***Care Delivery Segment***

Revenue for the three months ended March 31, 2026, was $85.1 million, as compared to $33.4 million for the three months ended March 31, 2025, an increase of $51.7 million. Operating loss for the three months ended March 31, 2026, was $3.0 million, as compared to loss of $3.1 million for the three months ended March 31, 2025, an increase in operating income of $0.1 million. The increase in revenue was primarily driven by $49.9 million of revenue from the inclusion of Prospect, as well as an increased volume in patient visits and continued investments at our primary, multi-specialty, and ancillary Care Delivery entities.

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Care Enablement Segment***

Revenue for the three months ended March 31, 2026, was $87.7 million, as compared to $39.6 million for the three months ended March 31, 2025, an increase of $48.2 million. Operating income for the three months ended March 31, 2026 was $20.2 million, as compared to operating income of $3.5 million for the three months ended March 31, 2025, an increase of $16.6 million. The increase in revenue and operating income was primarily due to managing more IPAs in our Care Partners segment and through new external contracts, including those acquired through Prospect, including $40.8 million in revenue and $13.6 million in operating income contributed by the Prospect acquisition. As of March 31, 2026 and 2025, the total number of affiliated physician groups we managed were 29 and 20 groups, respectively.

**Reconciliation of Net Income to EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin** 

Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA, as well as the reconciliations to Adjusted EBITDA margin for the three months ended March 31, 2026 and 2025.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| ***(in thousands)*** | **2026** | **2025** |
| Net income | $13131 | $6221 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 16101 | 7308 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (3816) | (2312) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 6578 | 3383 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 15479 | 6849 |
| **EBITDA** | 47473 | 21449 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) loss from equity method investments | (1720) | 867 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 10650<br><sup>(1)</sup> | 6259<br><sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 9895 | 7811 |
| **Adjusted EBITDA** | $66298 | $36386 |
| **Total revenue** | $965100 | $620390 |
| **Adjusted EBITDA margin** | 7% | 6% |

---

<sup>(1)</sup> Other, net, for the three months ended March 31, 2026, relates to an allowance on receivables that the Company plans to recover from the payer, post-acquisition integration costs, and severance fees incurred.

<sup>(2)</sup> Other, net, for the three months ended March 31, 2025, relates to debt issuance costs expensed in connection with our Second Amended and Restated Credit Facility, transaction costs for our acquisition of Prospect, certain costs for some of our acquisitions, non-cash changes related to change in the fair value of our call option and collar agreement, and severance fees incurred.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted**

Set forth below are reconciliations of net income to adjusted net income attributable to Astrana as well as the reconciliations to adjusted EPS - diluted for the three months ended March 31, 2026 and 2025.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| ***(in thousands, except for share and per share data)*** | **2026** | **2025** |
| Net income | $13131 | $6221 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) loss from equity method investments | (1720) | 867 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net <sup>(1)</sup> | 10650 | 6259 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 9895 | 7811 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets attributable to acquisitions | 13850 | 6263 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax adjustments | (7525)<sup>(2)</sup> | (4602)<sup>(3)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income attributable to non-controlling interests | (1928)<sup>(4)</sup> | (2317)<sup>(5)</sup> |
| **Adjusted net income attributable to Astrana Health, Inc.** | $36353 | $20502 |
| Weighted average shares of common stock outstanding – diluted | 49054135 | 48850666 |
| **Adjusted earnings per share - diluted** | $0.74 | $0.42 |

---

<sup>(1)</sup> The components of other, net, as set forth in the table above, are described in the footnotes to the table under "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin". Please see the footnotes to such table for additional information.

<sup>(2)</sup> Tax adjustments for the three months ended March 31, 2026, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $8.9 million, partially offset by 162(m) impact of $1.3 million.

<sup>(3)</sup> Tax adjustments for the three months ended March 31, 2025, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $5.7 million, partially offset by 162(m) impact of $1.1 million.

<sup>(4)</sup> Includes net loss attributable to non-controlling interests ("NCI") of $1.3 million, offset by adjustments attributable to NCI of $3.2 million, for the three months ended March 31, 2026.

<sup>(5)</sup> Includes net loss attributable to NCI of $0.5 million, offset by adjustments attributable to NCI of $2.8 million, for the three months ended March 31, 2025.

**Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow**

The following table provides a reconciliation of net cash provided by operating activities to free cash flow for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| ***(in thousands)*** | **2026** | **2025** |
| Net cash provided by operating activities | $68056 | $16627 |
| Purchases of property and equipment | (4000) | (3070) |
| **Free cash flow** | $64056 | $13557 |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

*Use of Non-GAAP Financial Measures*

This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS - diluted, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. This Quarterly Report on Form 10-Q also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S. GAAP is net cash provided by operating activities. These measures are not in accordance with, or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. We use Adjusted EBITDA, Adjusted EBITDA margin, adjusted EPS - diluted, and free cash flow as supplemental performance measures of our operations, for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. We define Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments, and amounts related to net income or loss attributable to non-controlling interests. We define adjusted EPS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. We define free cash flow as net cash provided by operating activities minus cash used in purchases of property and equipment.

We believe the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, adjusted EPS - diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this Form 10-Q contains historical or future non-GAAP financial measures, we have provided corresponding GAAP financial measures for comparative purposes. The reconciliations between certain GAAP and non-GAAP measures are provided above.

**Liquidity and Capital Resources**

Cash and cash equivalents at March 31, 2026, totaled $478.4 million, as compared to $429.5 million at December 31, 2025. Working capital totaled $258.7 million at March 31, 2026, as compared to $248.0 million at December 31, 2025, an increase of $10.7 million.

We have historically financed our operations primarily through internally generated funds and borrowings on long-term debt. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, FFS reimbursements, and other revenues. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. In February 2025, we entered into the Second Amended and Restated Credit Agreement, which amended and restated that certain amended credit agreement and provides for a five-year revolving credit facility of $300.0 million, a term loan of $250.0 million, and a delayed-draw term loan that was drawn for $707.3 million in July 2025, which we primarily used to refinance certain existing indebtedness and to fund the costs associated with the Prospect acquisition. We had $138.0 million remaining available under the revolving credit facility as of March 31, 2026. In addition, we have a current shelf registration statement filed with the SEC under which we may issue common stock, preferred stock, debt securities, and other securities that may be offered in one or more offerings on terms to be determined at the time of the offering. We believe we have sufficient liquidity to fund our operations through at least the next 12 months and the foreseeable future.

------

[<u>**Table of Contents**</u>](#table_of_contents)

***Cash Flow Activities***

Our cash flows are summarized as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Net cash provided by operating activities | $68056 | $16627 | $51429 | 309% |
| Net cash used in investing activities | (2844) | (2394) | (450) | 19% |
| Net cash used in financing activities | (15960) | (44170) | 28210 | (64)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash, cash equivalents, and restricted cash | $49252 | $(29937) | $79189 | (265)% |

---

*Operating Activities*

Cash provided by operating activities for the three months ended March 31, 2026, was $68.1 million, as compared to cash provided by operating activities of $16.6 million for the three months ended March 31, 2025. The increase in cash provided by operating activities was primarily driven by favorable changes in working capital relative to the three months ended March 31, 2025 and higher adjusted net income. The change in working capital for the 2026 and 2025 periods included timing of claims payments related to our medical liabilities, timing of payments for provider incentives, and a decrease in cash paid for income taxes. For the three months ended March 31, 2026, net income, exclusive of depreciation and amortization, amortization of debt issuance cost, share-based compensation, non-cash lease expense, deferred tax, change in fair value of contingent consideration liabilities, and other was $41.6 million, as compared to $24.6 million for the three months ended March 31, 2025.

*Investing Activities*

Cash used in investing activities during the three months ended March 31, 2026, was $2.8 million, primarily due to purchases of property and equipment for $4.0 million. Cash used in investing activities during the three months ended March 31, 2025, was $2.4 million primarily due to purchases of property and equipment of $3.1 million.

*Financing Activities*

Cash used in financing activities during the three months ended March 31, 2026, was $16.0 million, primarily due to repayments of debt of $12.0 million, repurchase of treasury shares of $2.9 million, tax payments from net share settlement of restricted stock awards and units of $1.2 million, and dividend payments of $0.1 million. Cash used in financing activities during the three months ended March 31, 2025, was $44.2 million, primarily due to repayments of debt of $428.2 million, payments of deferred financing costs of $17.2 million, dividends paid of $5.5 million, and taxes paid from net share settlement of restricted stock of $4.1 million, partially offset by borrowings on debt of $412.0 million.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**Credit Facility**

The following are the future commitments of our debt for the years ending December 31 (in thousands) below:

---

| | |
|:---|:---|
|  | **Amount** |
| 2026 (excluding the three months ended March 31, 2026) | $35898 |
| 2027 | 65814 |
| 2028 | 71798 |
| 2029 | 89747 |
| 2030 | 777019 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $1040276 |

---

***Second Amended and Restated Credit Agreement***

The Second Amended and Restated Credit Agreement provides for (a) a five-year revolving credit facility to the Company of $300.0 million, which includes a letter of credit sub-facility of up to $100.0 million and a swingline loan sub-facility of $25.0 million, (b) a five-year term loan A credit facility to the Company of $250.0 million, and (c) a five-year delayed draw term loan credit facility to the Company of $745.0 million, of which $707.3 million was drawn down, and the remainder of the commitment terminated, in connection with closing the Prospect acquisition. The five-year revolving credit facility and the Term Loans mature on February 26, 2030.

See Note 8 — "Credit Facility and Bank Loans" to our condensed consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information on our debt obligations.

**Critical Accounting Policies and Estimates**

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities reported in our condensed consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which management uses judgment, assumptions, and estimates in applying these policies is therefore integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that reflect significant judgments and uncertainties, potentially resulting in materially different results under different assumptions and conditions. We summarize our most significant accounting policies in relation to the accompanying condensed consolidated financial statements in Note 2 — "Basis of Presentation and Summary of Significant Accounting Policies" thereto. Please also refer to the Critical Accounting Policies section of Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

**Off-Balance Sheet Arrangements**

As of March 31, 2026, we had no off-balance sheet arrangements that are, or have been, reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Interest Rate Risk**

Borrowings under the Term Loans and Revolver Loan provided for under our Second Amended and Restated Credit Agreement, as of March 31, 2026, were $918.3 million and $122.0 million, respectively. The loans under the Second Amended and Restated Credit Agreement bear interest at an annual rate equal to either, at our option, (a) the rate for term SOFR published by the CME Group Benchmark Administration Limited two days prior to the first day of the applicable interest period, plus a spread of 1.25% to 2.50%, as determined on a quarterly basis based on the Company's leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company's leverage ratio. We have entered into an interest swap agreement to effectively convert our floating-rate debt to a fixed-rate basis with a termination date of August 31, 2029, provided that the bank has the right to change the swap to a two-year term. The interest swap agreement sets a fixed rate of 3.179% for the first $200.0 million of our aggregate debt balance. The principal objective of the swap agreement is to eliminate or reduce the variability of cash flows associated with our floating-rate debt, thereby reducing the impact of interest rate changes on future interest payment cash flows. Based on our current outstanding borrowings as of March 31, 2026, a hypothetical 1% change in our interest rates would increase or decrease our interest expense, on an annual basis, by $8.4 million.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

We maintain "disclosure controls and procedures," as defined in Rule 13a-15(e) under the Exchange Act, designed to ensure that information required to be disclosed by a company in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well-designed and well-operated, can provide only reasonable assurance of achieving their objectives.

As of March 31, 2026, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial and Operating Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. As previously disclosed in the Form 10-K for the year ended December 31, 2025, management identified a material weakness in internal control over financial reporting associated with the accounting for business combinations. Because this material weakness had not been remediated as of March 31, 2026, management concluded that our disclosure controls and procedures were not effective as of March 31, 2026. Notwithstanding the identified material weakness, our management, including our Chief Executive Officer and Chief Financial Officer, believes that the condensed consolidated financial statements fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in this Quarterly Report on Form 10-Q, in accordance with accounting principles generally accepted in the United States.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Following the identification of the material weakness described in the Form 10-K for the year ended December 31, 2025, management is continuing to make progress in its design and implementation of remediation activities to address the material weakness, and therefore these remediation activities are not reflected as changes in internal control over financial reporting for the quarter ended March 31, 2026. We excluded the operations of Prospect as we continue to evaluate its internal control over financial reporting. This exclusion is in accordance with the general guidance issued by the Staff of the Securities and Exchange Commission that an assessment of a recent business combination may be omitted from management's report on internal control over financial reporting in the first year of consolidation.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**PART II – OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

We are, from time to time, party to lawsuits, threatened lawsuits, disputes, and other claims arising in the normal course of business. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal accruals may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable, or the amount of the loss is not estimable, we do not record an accrual, in accordance with applicable accounting guidance. In the opinion of management, while the outcome of such claims and disputes cannot be predicted with certainty, our ultimate liability in connection with these matters is not expected to have a material adverse effect on our results of operations, financial position, or cash flows, and except as described under "Litigation" in Note 11 — "Commitments and Contingencies," to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q, the amounts accrued for any individual matter are not material. However, legal proceedings are inherently uncertain. As a result, the outcome of a particular matter or a combination of matters may be material to our results of operations for a particular period, depending upon the size of the loss or our income for that particular period.

Certain of the pending or threatened legal proceedings or claims in which we are involved are discussed under Note 11 — "Commitments and Contingencies," to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q, which disclosure is incorporated by reference herein.

**ITEM 1A. RISK FACTORS**

Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026. The risks disclosed in such Annual Report could materially adversely affect our business, financial condition, cash flows, or results of operations, and thus our stock price. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect the Company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.

Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. In addition, the disclosure of any risk factor should not be interpreted to imply that the risk has not already materialized.

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

In December 2022, Astrana's Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $50.0 million of its shares of common stock. In February 2026, the Board of Directors increased the total authorization under the share repurchase program to $100.0 million of its shares of common stock, including the $35.9 million that remained available under the previously announced stock repurchase program. Repurchases may be made through a variety of methods, which could include open market purchases, accelerated share repurchase transactions, negotiated block transactions, 10b5-1 plans, other transactions that may be structured through investment banking institutions or privately negotiated, or a combination of the foregoing. This share repurchase program has no expiration date. The Board may suspend, modify, or discontinue the repurchase program at any time. This repurchase program does not obligate the Company to make additional repurchases at any specific time or in any specific situation. During the three months ended March 31, 2026, 124,747 shares were repurchased under the Company's share repurchase program. As of March 31, 2026, $83.1 million remained available under the repurchase program.

The following table provides information about purchases made by the Company of shares of the Company's common stock during the three months ended March 31, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number<br>of Shares<br>Purchased** <sup>(1)</sup> | **Average Price<br>Paid Per<br>Share** | **Total Number of<br>Shares<br>Purchased as<br>Part of Publicly<br>Announced Plans<br>or Programs** | **Approximate Dollar<br>Value of Shares That<br>May Yet Be<br>Purchased Under the<br>Plans or Programs<br>(in thousands)** |
| January 1, 2026 to January 31, 2026 | 141882 | $22.96 | 123566 | $33132 |
| February 1, 2026 to February 28, 2026 | 1292 | $22.28 | 1181 | $83105 |
| March 1, 2026 to March 31, 2026 | 20742 | $24.92 |  | $83105 |
| Total | 163916 | $23.21 | 124747 |  |

---

<sup>(1)</sup> Includes 39,169 shares repurchased to satisfy tax withholding obligations due upon the vesting of restricted stock awards held by certain employees. We did not pay cash to repurchase these shares, nor were these repurchases part of a publicly announced plan or program.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

*Rule 10b5-1 Trading Plans* 

During the quarter ended March 31, 2026, none of the Company's directors or executive officers adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K).

------

[<u>**Table of Contents**</u>](#table_of_contents)

**ITEM 6. EXHIBITS**

The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 2.1† | [<u>Agreement and Plan of Merger, dated December 21, 2016, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa) |
| 2.2 | [<u>Amendment to the Agreement and Plan of Merger, dated March 30, 2017, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa) |
| 2.3 | [<u>Amendment No. 2 to the Agreement and Plan of Merger, dated October 17, 2017, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm) |
| 2.4† | [<u>Asset and Equity Purchase Agreement, dated November 8, 2024, by and among Astrana Health, Inc., PHP Holdings, LLC, PHS Holdings, LLC, Prospect Intermediate Holdings, LLC, each of the entities set forth on Schedule C of the agreement, and Prospect Medical Holdings, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on November 8, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000110465924115969/tm2427779d2_ex2-1.htm) |
| 3.1 | [<u>Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on January 21, 2015)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm) |
| 3.2 | [<u>Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on April 27, 2015)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm) |
| 3.3 | [<u>Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 13, 2017)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm) |
| 3.4 | [<u>Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 21, 2018)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm) |
| 3.5 | [<u>Certificate of Amendment of Restated Certificate of Incorporation (effective February 26, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on January 26, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000110465924006988/tm244161d1_ex3-1.htm) |
| 3.6 | [<u>Certificate of Amendment of Restated Certificate of Incorporation (effective June 13, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 13, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000110465924071275/tm2416686d1_ex3-1.htm) |
| 3.7 | [<u>Amended and Restated By-laws (effective February 28, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 29, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1083446/000110465924028972/tm247268d2_ex3-1.htm) |
| 31.1\* | [<u>Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](asth-ex31_1.htm) |

---

------

[<u>**Table of Contents**</u>](#table_of_contents)

---

| | |
|:---|:---|
| 31.2\* | [<u>Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>](asth-ex31_2.htm) |
| 32\*\* | [<u>Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>](asth-ex32.htm) |
| 101.INS\* | Inline XBRL Instance Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\* Filed herewith.

\*\* Furnished herewith.

+ Management contract or compensatory plan, contract or arrangement.

† Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

------

[<u>**Table of Contents**</u>](#table_of_contents)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASTRANA HEALTH, INC.** | **ASTRANA HEALTH, INC.** |
| May 8, 2026 | By: | /s/ Brandon K. Sim |
|  |  | Brandon K. Sim, M.S.<br>Chief Executive Officer and President<br>(Principal Executive Officer) |
| May 8, 2026 | By: | /s/ Chandan Basho |
|  |  | Chandan Basho, M.B.A.<br>Chief Financial and Operating Officer<br>(Principal Financial Officer) |

---

------

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brandon K. Sim, M.S., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Astrana Health, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

---

| | | |
|:---|:---|:---|
| Date: | May 8, 2026 | /s/ Brandon K. Sim |
|  |  | **Brandon K. Sim, M.S.**<br>Chief Executive Officer & President<br>(Principal Executive Officer) |

---

------

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Chandan Basho, M.B.A., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Astrana Health, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

---

| | | |
|:---|:---|:---|
| Date: | May 8, 2026 | /s/ Chandan Basho |
|  |  | **Chandan Basho, M.B.A.**<br>Chief Financial Officer and Chief Operating Officer<br>(Principal Financial Officer) |

---

------

## Ex-32

**EXHIBIT 32**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350.**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brandon K. Sim, M.S., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Astrana Health, Inc. for the quarter ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Astrana Health, Inc.

---

| | | |
|:---|:---|:---|
| Date:  | May 8, 2026 | /s/ Brandon K. Sim |
|  |  | **Brandon K. Sim, M.S.**<br>Chief Executive Officer and President<br>(Principal Executive Officer) |

---

I, Chandan Basho, M.B.A., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Astrana Health, Inc. for the quarter ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Astrana Health, Inc.

---

| | | |
|:---|:---|:---|
| Date:  | May 8, 2026 | /s/ Chandan Basho |
|  |  | **Chandan Basho, M.B.A.**<br>Chief Financial Officer and Chief Operating Officer<br>(Principal Financial Officer) |

---

------